WO2000065521A2 - System and method for polymer notation - Google Patents

System and method for polymer notation Download PDF

Info

Publication number
WO2000065521A2
WO2000065521A2 PCT/US2000/010990 US0010990W WO0065521A2 WO 2000065521 A2 WO2000065521 A2 WO 2000065521A2 US 0010990 W US0010990 W US 0010990W WO 0065521 A2 WO0065521 A2 WO 0065521A2
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
data structure
polymers
properties
chemical
Prior art date
Application number
PCT/US2000/010990
Other languages
English (en)
French (fr)
Other versions
WO2000065521A3 (en
Inventor
Ganesh Venkataraman
Zachary Shriver
Rahul Raman
Ram Sasisekharan
Nishla Keiser
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to EP00923599A priority Critical patent/EP1190364A2/en
Priority to JP2000614193A priority patent/JP4824170B2/ja
Priority to CA002370539A priority patent/CA2370539C/en
Publication of WO2000065521A2 publication Critical patent/WO2000065521A2/en
Publication of WO2000065521A3 publication Critical patent/WO2000065521A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/30Data warehousing; Computing architectures
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • G16B50/40Encryption of genetic data
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16CCOMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/20Identification of molecular entities, parts thereof or of chemical compositions
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00ICT programming tools or database systems specially adapted for bioinformatics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/99931Database or file accessing
    • Y10S707/99933Query processing, i.e. searching
    • Y10S707/99936Pattern matching access
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S707/00Data processing: database and file management or data structures
    • Y10S707/99941Database schema or data structure
    • Y10S707/99943Generating database or data structure, e.g. via user interface

Definitions

  • notational systems have been used to encode classes of chemical units.
  • a unique code is assigned to each chemical unit in the class.
  • a polymer of chemical units can be represented, using such a notational system, as a set of codes corresponding to the chemical units.
  • Such notational systems have been used to encode polymers, such as proteins, in a computer-readable format.
  • a polymer that has been represented in a computer-readable format according to such a notational system can be processed by a computer.
  • Character-based searching algorithms are typically slow because such algorithms search by comparing individual characters in the query sequence against individual characters in the sequences of chemical units stored in the database. The speed of such algorithms is therefore related to the length of the query sequence, resulting in particularly poor performance for long query sequences.
  • Polymers may be characterized by identifying properties of the polymers and comparing those properties to reference polymers, a process referred to herein as property encoded nomenclature (PEN).
  • the properties are encoded using a binary notation system, and the comparison is accomplished by comparing the binary representations of polymers. For instance, in one aspect a sample polymer is subjected to an experimental constraint to modify the polymer, the modified polymer is compared to a reference database of polymers to identify a population of polymers having a property that is the same as or similar to a property of the sample polymer. The method may be repeated until the population of polymers in the reference database is reduced to one and the identity of the sample polymer is known.
  • PEN property encoded nomenclature
  • the invention is directed to a notational system for representing polymers of chemical units.
  • the notational system is referred to as Property encoded nomenclature (PEN).
  • PEN Property encoded nomenclature
  • a polymer is assigned an identifier that includes information about properties of the polymer.
  • properties of a disaccharide are each assigned a binary value, and an identifier for the disaccharide includes the binary values assigned to the properties of the disaccharide.
  • the identifier is capable of being expressed as a number, such as a single hexadecimal digit.
  • the identifier may be stored in a computer readable medium, such as in a data unit (e.g., record or table entry) of a polymer database.
  • Polymer identifiers may be used in a number of ways. For example, the identifiers may be used to determine whether properties of a query sequence of chemical units match properties of a polymer of chemical units. One application of such matching is to quickly search a polymer database for a particular polymer of interest or for a polymer or polymers having specified properties.
  • the invention is directed to a data structure, tangibly embodied in a computer-readable medium, representing a polymer of chemical units.
  • the invention is directed to a computer-implemented method for generating such a data structure.
  • the data structure may include an identifier that may include one or more fields for storing values corresponding to properties of the polymer. At least one field may be a non-character-based field. Each field may be capable of storing a binary value.
  • the identifier may be a numerical identifier, such as a number that is representable as a single-digit hexadecimal number.
  • the polymer may be any of a variety of polymers.
  • the polymer may be a polysaccharide and the chemical units may be saccharides; (2) the polymer may be a nucleic acid and the chemical units may be nucleotides; or (3) the polymer may be a polypeptide and the chemical units may be amino acids.
  • the properties may be properties of the chemical units in the polymer.
  • the properties may include charges of chemical units in the polymer, identities of chemical units in the polymer, confirmations of chemical units in the polymer, or identities of substituents of chemical units in the polymer.
  • the properties may be properties of the polymer that are not properties of any individual chemical unit within the polymer.
  • Example properties include a total charge of the polymer, a total number of sulfates of the polymer, a dye-binding of the polymer, a mass of the polymer, compositional ratios of substituents, compositional ratios of iduronic versus glucuronic, enzymatic sensitivity, degree of sulfation, charge, and chirality.
  • the invention is directed to a computer-implemented method for determining whether properties of a query sequence of chemical units match properties of a polymer of chemical units.
  • the query sequence may be represented by a first data structure, tangibly embodied in a computer-readable medium, including an identifier that may include one or more bit fields for storing values corresponding to properties of the query sequence.
  • the polymer may be represented by a second data structure, tangibly embodied in a computer-readable medium, including an identifier that may include one or more bit fields for storing values corresponding to properties of the polymer.
  • the method may include acts of generating at least one mask based on the values stored in the one or more bit fields of the first data structure, performing at least one binary operation on the values stored in the one or more bit fields of the second data structure using the at least one mask to generate at least one result, and determining whether the properties of the query sequence match the properties of the polymer based on the at least one result.
  • the chemical units may, for example, be any of the chemical units described above.
  • the properties may be any of the properties described above.
  • the act of generating includes an act of generating the at least one mask as a sequence of bits that is equivalent to the values stored in the one or more bit fields of the first data structure. In another embodiment, the act of generating includes an act of generating the at least one mask as a sequential repetition of the values stored in the one or more bit fields of the first data structure.
  • the at least one mask includes a plurality of masks and the act of performing at least one binary operation includes acts of performing a logical AND operation on the values stored in the one or more bit fields of the second data structure using each of the plurality of masks to generate a plurality of intermediate results, and combining the plurality of intermediate results using at least one logical OR operation to generate the at least one result.
  • the act of determining includes an act of determining that the properties of the query sequence match the properties of the polymer when the at least one result has a non-zero value.
  • the at least one binary operation includes at least one logical AND operation.
  • the invention is directed to a database, tangibly embodied in a computer-readable medium, for storing information descriptive of one or more polymers.
  • the database may include one or more data units (e.g., records or table entries) corresponding to the one or more polymers, each of the data units may include an identifier that may include one or more fields for storing values corresponding to properties of the polymer.
  • the invention is directed to a data structure, tangibly embodied in a computer-readable medium, representing a chemical unit of a polymer.
  • the data structure may comprise an identifier including one or more fields. Each field may be for storing a value corresponding to one or more properties of the chemical unit. At least one field may store a non-character-based value such as, for example, a binary or decimal value.
  • Polymers may be characterized by identifying properties of the polymers and comparing those properties to reference polymers, a process referred to herein as property encoded nomenclature (PEN).
  • the properties are encoded using a binary notation system, and the comparison is accomplished by comparing the binary representations of polymers. For instance, in one aspect a sample polymer is subjected to an experimental constraint to modify the polymer, the modified polymer is compared to a reference database of polymers to identify a population of polymers having a property that is the same as or similar to a property of the sample polymer. The method may be repeated until the population of polymers in the reference database is reduced to one and the identity of the sample polymer is known.
  • PEN property encoded nomenclature
  • a method for determining the composition of a sample polymer of chemical units having a known molecular weight and length is provided according to one aspect of the invention.
  • the method includes the steps of
  • the method also includes the step of: (E) repeatedly performing the step (D) until the number of candidate polymers of chemical units falls below a predetermined threshold.
  • the invention is a method for identifying a population of polymers of chemical units having the same property as a sample polymer of chemical units. The method includes the steps of determining a property of a sample polymer of chemical units, and comparing the property of the sample polymer to a reference database of polymers of known sequence and known properties to identify a population of polymers of chemical units having the same property as a sample polymer of chemical units, wherein the reference database of polymers includes identifiers corresponding to the chemical units of the polymers, each of the identifiers including a field storing a value corresponding to the property.
  • the step of determining a property of the sample polymer involves the use of mass spectrometry, such as for example, matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), electron spray-MS, fast atom bombardment mass spectrometry (FAB-MS) and collision-activated dissociation mass spectrometry (CAD) to determine the molecular weight of the polymer.
  • mass spectrometry such as for example, matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), electron spray-MS, fast atom bombardment mass spectrometry (FAB-MS) and collision-activated dissociation mass spectrometry (CAD) to determine the molecular weight of the polymer.
  • MALDI-MS matrix assisted laser desorption ionization mass spectrometry
  • FAB-MS fast atom bombardment mass spectrometry
  • CAD collision-activated dissociation mass spectrometry
  • the step of identifying a property of the polymer in other embodiments may involve the reduction in size of the polymer into pieces of several units in length that may be detected by strong ion exchange chromatography.
  • the fragments of the polymer may be compared to the reference database polymers.
  • the invention is a method for identifying a subpopulation of polymers having a property in common with a sample polymer of chemical units.
  • the method involves the steps of applying an experimental constraint to the polymer to modify the polymer, detecting a property of the modified polymer, identifying a population of polymers of chemical units having the same molecular length as the sample polymer, and identifying a subpopulation of the identified population of polymers having the same property as the modified polymer by eliminating, from the identified population of polymers, polymers having properties that do not correspond to the modified polymer.
  • the steps may be repeated on the modified polymer to identify a second subpopulation within the subpopulation of polymers having a second property in common with the twice modified polymer. Each of the steps may then be repeated until the number of polymers within the subpopulation falls below a predetermined threshold.
  • the method may be performed to identify the sequence of the polymer. In this case the predetermined threshold of polymers within the subpopulation is two polymers.
  • the invention is a method for identifying a subpopulation of polymers having a property in common with a sample polymer of chemical units.
  • the method involves the steps of applying an experimental constraint to the polymer to modify the polymer, detecting a first property of the modified polymer, identifying a population of polymers of chemical units having a second property in common with the sample polymer, and identifying a subpopulation of the identified population of polymers having the same first property as the modified polymer by eliminating, from the identified population of polymers, polymers having properties that do not correspond to the modified polymer.
  • the experimental constraints applied to the polymer are different for each repetition.
  • the experimental constrain may be any manipulation which alters the polymer in such a manner that it will be possible to derive structural information about the polymer or a unit of the polymer.
  • the experimental constraint applied to the polymer may be any one or more of the following constraints: enzymatic digestion, e.g., with an exoenzyme, an endoenzyme, a restriction endonuclease; chemical digestion; chemical modification; interaction with a binding compound; chemical peeling (i.e., removal of a monosaccharide unit); and enzymatic modification, for instance sulfation at a particular position with a heparin sulfate sulfotransferases.
  • the property of the polymer that is detected by the method of the invention may be any structural property of a polymer or unit.
  • the property of the polymer may be the molecular weight or length of the polymer.
  • the property may be the compositional ratios of substituents or units, type of basic building block of a polysaccharide, hydrophobicity, enzymatic sensitivity, hydrophilicity, secondary structure and conformation (i.e., position of helices), spatial distribution of substituents, ratio of one set of modifications to another set of modifications (i.e., relative amounts of 2-0 sulfation to N-sulfation or ratio of iduronic acid to glucuronic acid, and binding sites for proteins.
  • the properties of the modified polymer may be detected in any manner possible which depends on the property and polymer being analyzed.
  • the step of detection involves mass spectrometry such as matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), electron spray MS, fast atom bombardment mass spectrometry (FAB-MS) and collision-activated dissociation mass spectrometry (CAD).
  • mass spectrometry such as matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), electron spray MS, fast atom bombardment mass spectrometry (FAB-MS) and collision-activated dissociation mass spectrometry (CAD).
  • MALDI-MS matrix assisted laser desorption ionization mass spectrometry
  • FAB-MS fast atom bombardment mass spectrometry
  • CAD collision-activated dissociation mass spectrometry
  • the step of detection involves strong ion exchange chromatography, for example, if the polymer has been digested into several smaller fragments composed of several units
  • the method is based on a comparison of the sample polymer with a population of polymers of the same length or having at least one property in common.
  • the population of polymers of chemical units includes every polymer sequence having the molecular weight of the sample polymer.
  • the population of polymers of chemical units includes less than every polymer sequence having the molecular weight of the sample polymer.
  • the step of identifying includes selecting the population of polymers of chemical units from a database including molecular weights of polymers of chemical units.
  • the database includes identifiers corresponding to chemical units of a plurality of polymers, each of the identifiers including a field storing a value corresponding to a property of the corresponding chemical unit.
  • a method for compositional analysis of a sample polymer includes the steps of applying an experimental constraint to the sample polymer to modify the sample polymer, detecting a property of the modified sample polymer, and comparing the modified sample polymer to a reference database of polymers of identical size as the polymer, wherein the polymers of the reference database have also been subjected to the same experimental constraint as the sample polymer, wherein the comparison provides a compositional analysis of the sample polymer.
  • compositional analysis reveals the number and type of units within the polymer. In other embodiments the compositional analysis reveals the identity of a sequence of chemical units of the polymer.
  • the properties of the polymer may be detected in any manner possible and will depend on the particular property and polymer being analyzed.
  • the step of detection involves mass spectrometry such as matrix assisted laser desorption ionization mass spectrometry (MALDI-MS), electron spray MS, fast atom bombardment mass spectrometry (FAB- MS) and collision-activated dissociation mass spectrometry (CAD).
  • MALDI-MS matrix assisted laser desorption ionization mass spectrometry
  • FAB- MS fast atom bombardment mass spectrometry
  • CAD collision-activated dissociation mass spectrometry
  • the experimental constraint applied to the polymer is an enzymatic or chemical reaction which involves incomplete enzymatic digestion of the polymer and wherein the steps of the method are repeated until the number of polymers within the reference database falls below a predetermined threshold.
  • the step of detection involves capillary electrophoresis, particularly when the experimental constraint applied to the polymer involves complete degradation of the polymer into individual chemical units.
  • the reference database includes identifiers corresponding to chemical units of a plurality of polymers, each of the identifiers including a field storing a value corresponding to a property of the corresponding chemical unit.
  • a method for sequencing a polymer includes the steps of applying an experimental constraint to the polymer to modify the polymer, detecting a property of the modified polymer, identifying a population of polymers having the same molecular length as the sample polymer and having molecular weights similar to the molecular weight of the sample polymer, identifying a subpopulation of the identified population of polymers having the same property as the modified polymer by eliminating, from the identified population of polymers, polymers having properties that do not correspond to the modified polymer, and repeating the steps applying an experimental constraint, detecting a property and identifying a subpopulation by applying additional experimental constraints to the polymer and identifying additional subpopulations of polymers until the number of polymers within the subpopulation is one and the sequence of the polymer may be identified.
  • the invention in another aspect relates to a method for identifying a polysaccharide-protein interaction, by contacting a protein-coated MALDI surface with a polysaccharide containing sample to produce a polysaccharide-protein-coated MALDI surface, removing unbound polysaccharide from the polysaccharide-protein-coated MALDI surface, and performing MALDI mass spectrometry to identify the polysaccharide that specifically interacts with the protein coated on the MALDI surface.
  • a MALDI matrix is added to the polysaccharide-protein- coated MALDI surface.
  • an experimental constraint may be applied to the polysaccharide bound on the polysaccharide-protein-coated MALDI surface before performing the MALDI mass spectrometry analysis.
  • the experimental constraint applied to the polymer in some embodiments is digestion with an exoenzyme or digestion with an endoenzyme. In other embodiments the experimental constraint applied to the polymer is selected from the group consisting of restriction endonuclease digestion; chemical digestion; chemical modification; and enzymatic modification.
  • FIG. 1 is a block diagram illustrating an example of a computer system for storing and manipulating polymer information.
  • FIG. 2A is a diagram illustrating an example of a record for storing information about a polymer and its constituent chemical units.
  • FIG. 2B is a diagram illustrating an example of a record for storing information about a polymer.
  • FIG. 2C is a diagram illustrating an example of a record for storing information about constituent chemical units of a polymer.
  • FIG. 3 is a flow chart illustrating an example of a method for determining whether properties of a first polymer of chemical units match properties of a second chemical unit.
  • FIG. 4 is a dataflow diagram of a system for sequencing a polymer.
  • FIG. 5 is a flow chart of a process for sequencing a polymer.
  • FIG. 6 is a flow chart of a process for sequencing a polymer using a genetic algorithm.
  • FIG. 7A-D is a set of diagrams depicting notation schemes for branched chain analysis.
  • FIG. 8 is a mass line diagram.
  • FIG. 9 is a mass-line diagram for (A) Polysialic Acid with NAN and (B) Polysialic Acid with NGN.
  • FIG. 10 is a graph (A) depicting cleavage by Hep III of either G(»), I(O) or I s(*) linkages, and a graph (B) depicting same study as in A but where cleavage was performed with Hep I.
  • FIG. 11 is a graph depicting MALDI-MS analysis of the extended core structures derived from enzymatic treatment of a mixture of bi- and triantennary structures.
  • FIG. 12 is a graph depicting MALDI-MS analysis of the PSA polysaccharide.
  • A intact polysaccharide structure.
  • B Treatment of [A] with sialidase from A. urefaciens.
  • C Digest of [B] with galactosidase from S. pneumoniae.
  • D Digest of [C] with N- acetylhexosaminidase from S. pneumoniae.
  • Peaks marked with an asterisk are impurities, and the analyte peak is detected both as M-H (m/z 2369.5) and as a monosodiated adduct (M+Na-2H, m/z 2392.6).
  • FIG. 13 is a graph depicting the results of enzymatic degradation of the saccharide chain directly off of PSA.
  • A PSA before the addition of exoenzymes.
  • B Treatment of (A) with sialidase results in a mass decrease of 287 Da, consistent with the loss of one sialic acid residue.
  • C Treatment of (B) with galactosidase.
  • D Upon digestion of (C) with hexosaminidase, a decrease of 393 Da indicates the loss of two N- acetylglucosamine residues.
  • FIG. 14 is a graph depicting the results of treatment of biantennary and triantennary saccharides with endoglycanse F2.
  • the invention relates in some aspects to methods for characterizing polymers to identify structural properties of the polymers, such as the charge, the nature and number of units of the polymer, the nature and number of chemical substituents on the units, and the stereospecificity of the polymer.
  • the structural properties of polymers may provide useful information about the function of the polymer. For instance, the properties of the polymer may reveal the entire sequence of units of the polymer, which is useful for identifying the polymer. Similarly, if the sequence of the polymer was previously unknown, the structural properties of the polymer are useful for comparing the polymer to known polymers having known functions.
  • the properties of the polymer may also reveal that a polymer has a net charge or has regions which are charged.
  • This information is useful for identifying compounds that the polymer may interact with or predicting which regions of a polymer may be involved in a binding interaction or have a specific function.
  • Many methods have been described in the prior art for identifying polymers and in particular for identifying the sequence of units of polymers.
  • the sequence information is stored in a database and may be used to compare the polymer with other sequenced polymers.
  • Databases such as GENBANK enable the storage and retrieval of information relating to the sequences of nucleic acids which have been identified by researchers all over the world. These databases typically store information using notational systems that encode classes of chemical units by assigning a unique code to each chemical unit in the class.
  • a conventional notational system for encoding amino acids assigns a single letter of the alphabet to each known amino acid.
  • databases represent a polymer of chemical units using a set of codes corresponding to the chemical units. Searches of such databases have typically been performed using character-based comparison algorithms.
  • PEN property encoded nomenclature
  • the invention is based on the identification and characterization of properties of a polymer, rather than units of the polymer, and the use of numeric identifiers to classify those properties and to facilitate information processing relating to the polymer.
  • the ability to identify properties of polymers and to manipulate the information concerning the properties of the polymer provide many advantages over prior art methods of characterizing polymers and Bioinformatics.
  • the methods of the invention may be used to identify structural information and analyze complex polymers such as polysaccharides which were previously very difficult to analyze using prior art methods.
  • FIG. 1 shows an example of a computer system 100 for storing and manipulating polymer information.
  • the computer system 100 includes a polymer database 102 which includes a plurality of records 104a- « storing information corresponding to a plurality of polymers.
  • Each of the records 104a- « may store information about properties of the corresponding polymer, properties of the corresponding polymer's constituent chemical units, or both.
  • the polymers for which information is stored in the polymer database 102 may be any kind of polymers.
  • the polymers may include polysaccharides, nucleic acids, or polypeptides.
  • a "polymer” as used herein is a compound having a linear and/or branched backbone of chemical units which are secured together by linkages.
  • backbone of the polymer may be branched.
  • backbone is given its usual meaning in the field of polymer chemistry.
  • the polymers may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide- nucleic acids.
  • the polymers are homogeneous in backbone composition and are, for example, a nucleic acid, a polypeptide, a polysaccharide, a carbohydrate, a polyurethane, a polycarbonate, a polyurea, a polyethyleneimine, a polyarylene sulfide, a polysiloxane, a polyimide, a polyacetate, a polyamide, a polyester, or a polythioester.
  • a "polysaccharide” is a biopolymer comprised of linked saccharide or sugar units.
  • nucleic acid as used herein is a biopolymer comprised of nucleotides, such as deoxyribose nucleic acid (DNA) or ribose nucleic acid (RNA).
  • a polypeptide as used herein is a biopolymer comprised of linked amino acids.
  • linked units of a polymer means two entities are bound to one another by any physicochemical means. Any linkage known to those of ordinary skill in the art, covalent or non-covalent, is embraced. Such linkages are well known to those of ordinary skill in the art. Natural linkages, which are those ordinarily found in nature connecting the chemical units of a particular polymer, are most common. Natural linkages include, for instance, amide, ester and thioester linkages. The chemical units of a polymer analyzed by the methods of the invention may be linked, however, by synthetic or modified linkages. Polymers where the units are linked by covalent bonds will be most common but also include hydrogen bonded, etc.
  • the polymer is made up of a plurality of chemical units.
  • a "chemical unit” as used herein is a building block or monomer which can be linked directly or indirectly to other building blocks or monomers to form a polymer.
  • the polymer preferably is a polymer of at least two different linked units. The particular type of unit will depend on the type of polymer.
  • DNA is a biopolymer comprised of a deoxyribose phosphate backbone composed of units of purines and pyrimidines such as adenine, cytosine, guanine, thymine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.
  • RNA is a biopolymer comprised of a ribose phosphate backbone composed of units of purines and pyrimidines such as those described for DNA but wherein uracil is substituted for thymidine.
  • DNA units may be linked to the other units of the polymer by their 5' or 3' hydroxyl group thereby forming an ester linkage.
  • RNA units may be linked to the other units of the polymer by their 5', 3' or 2' hydroxyl group thereby forming an ester linkage.
  • DNA or RNA units having a terminal 5', 3' or 2' amino group may be linked to the other units of the polymer by the amino group thereby forming an amide linkage.
  • the chemical units of a polypeptide are amino acids, including the 20 naturally occurring amino acids as well as modified amino acids.
  • Amino acids may exist as amides or free acids and are linked to the other units in the backbone of the polymers through their a-amino group thereby forming an amide linkage to the polymer.
  • a polysaccharide is a polymer composed of monosaccharides linked to one another.
  • the basic building block of the polysaccharide is actually a disaccharide unit which can be repeating or non-repeating.
  • a unit when used with respect to a polysaccharide refers to a basic building block of a polysaccharide and can include a monomeric building block (mono saccharide) or a dimeric building block (disaccharide).
  • a "plurality of chemical units” is at least two units linked to one another.
  • the polymers may be native or naturally-occurring polymers which occur in nature or non-naturally occurring polymers which do not exist in nature.
  • the polymers typically include at least a portion of a naturally occurring polymer.
  • the polymers can be isolated or synthesized de novo.
  • the polymers can be isolated from natural sources e.g. purified, as by cleavage and gel separation or may be synthesized e.g.,(i) amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) synthesized by, for example, chemical synthesis; (iii) recombinantly produced by cloning, etc.
  • PCR polymerase chain reaction
  • Fig. 2A illustrates an example of the format of a data unit 200 in the polymer database 102 (i.e., one of the data units 104a- «).
  • the data unit 200 may include a polymer identifier (ID) 202 that identifies the polymer corresponding to the data unit 200.
  • the polymer ID 202 is described in more detail below with respect to FIG. 2B.
  • the data unit 200 also may include one or more chemical unit identifiers (IDs) 204a-/7 corresponding to chemical units that are constituents of the polymer corresponding to the data unit 200.
  • the chemical unit IDs 204a- « are described in more detail below with respect to FIG. 2C.
  • the data unit 200 may include only the polymer ID 202 or may only include one or more of the chemical unit IDs 204a- «.
  • FIG. 2B illustrates an example of the polymer ID 202.
  • the polymer ID 202 may include one or more fields 202a- « for storing information about properties of the polymer corresponding to the data unit 200 (FIG. 2A).
  • FIG. 2C illustrates an example of the chemical unit 204a.
  • the chemical unit ID 204a may include one ore more fields 206a-w for storing information about properties of the chemical unit corresponding to the chemical unit ID 204a.
  • the following description refers to the fields 206a- m of the chemical unit ID 204a, such description is equally applicable to the fields 202a- n of the polymer ID 202a (and the fields of the chemical unit IDs 204b- «).
  • the fields 206a- m of the chemical unit ID 204a may store any kind of value that is capable of being stored in a computer readable medium, such as, for example, a binary value, a hexadecimal value, an integral decimal value, or a floating point value.
  • Each field 2.6a-m may store information about any property of the corresponding chemical unit.
  • the invention is useful for identifying properties of polymers.
  • a "property" as used herein is a characteristic (e.g., structural characteristic) of the polymer that provides information (e.g., structural information) about the polymer.
  • the term property is used with respect to any polymer except a polysaccharide the property provides information other than the identity of a unit of the polymer or the polymer itself.
  • a compilation of several properties of a polymer may provide sufficient information to identify a chemical unit or even the entire polymer but the property of the polymer itself does not encompass the chemical basis of the chemical unit or polymer.
  • polysaccharides When the term property is used with respect to polysaccharides, to define a polysaccharide property, it has the same meaning as described above except that due to the complexity of the polysaccharide, a property may identify a type of monomeric building block of the polysaccharide.
  • Chemical units of polysaccharides are much more complex than chemical units of other polymers, such as nucleic acids and polypeptides.
  • the polysaccharide unit has more variables in addition to its basic chemical structure than other chemical units.
  • the polysaccharide may be acetylated or sulfated at several sites on the chemical unit, or it may be charged or uncharged.
  • one property of a polysaccharide may be the identity of one or more basic building blocks of the polysaccharides.
  • a basic building block alone may not provide information about the charge and the nature of substituents of the saccharide or disaccharide.
  • a building block of uronic acid may be iduronic or glucuronic acid.
  • Each of these building blocks may have additional substituents that add complexity to the structure of the chemical unit.
  • a single property may not identify such additional substitutes charges, etc., in addition to identifying a complete building block of a polysaccharide.
  • This information may be assembled from several properties.
  • a property of a polymer as used herein does not encompass an amino acid or nucleotide but does encompass a saccharide or disaccharide building block of a polysaccharide.
  • a type of property that provides information about a polymer may depend on a type of polymer being analyzed. For instance, if the polymer is a polysaccharide, properties such as charge, molecular weight, nature and degree of sulfation or acetylation, and type of saccharide may provide information about the polymer.
  • Properties may include, but are not limited to, charge, chirality, nature of substituents, quantity of substituents, molecular weight, molecular length, compositional ratios of substituents or units, type of basic building block of a polysaccharide, hydrophobicity, enzymatic sensitivity, hydrophilicity, secondary structure and conformation (i.e., position of helicies), spatial distribution of substituents, ratio of one set of modifications to another set of modifications (i.e., relative amounts of 2-0 sulfation to N-sulfation or ratio of iduronic acid to glucuronic acid), and binding sites for proteins.
  • a substituent, as used herein is an atom or group of atoms that substitute a unit, but are not themselves the units.
  • a property of a polymer may be identified by any means known in the art.
  • the procedure used to identify a property may depend on a type of property.
  • Molecular weight for instance, may be determined by several methods including mass spectrometry.
  • mass spectrometry for determining the molecular weight of polymers is well known in the art.
  • Mass Spectrometry has been used as a powerful tool to characterize polymers because of its accuracy ( ⁇ lDalton) in reporting the masses of fragments generated (e.g., by enzymatic cleavage), and also because only pM sample concentrations are required.
  • MALDI-MS matrix-assisted laser desorption ionization mass spectrometry
  • mass spectrometry known in the art, such as, electron spray-MS, fast atom bombardment mass spectrometry (FAB- MS) and collision-activated dissociation mass spectrometry (CAD) can also be used to identify the molecular weight of the polymer or polymer fragments.
  • FAB- MS fast atom bombardment mass spectrometry
  • CAD collision-activated dissociation mass spectrometry
  • the mass spectrometry data may be a valuable tool to ascertain information about the polymer fragment sizes after the polymer has undergone degradation with enzymes or chemicals. After a molecular weight of a polymer is identified, it may be compared to molecular weights of other known polymers. Because masses obtained from the mass spectrometry data are accurate to one Dalton (ID), a size of one or more polymer fragments obtained by enzymatic digestion may be precisely determined, and a number of substituents (i.e., sulfates and acetate groups present) may be determined.
  • ID Dalton
  • a "mass line” as used herein is an information database, preferably in the form of a graph or chart which stores information for each possible type of polymer having a unique sequence based on the molecular weight of the polymer.
  • a mass line may describe a number of polymers having a particular molecular weight.
  • a two-unit nucleic acid molecule i.e., a nucleic acid having two chemical units
  • a two-unit polysaccharide i.e., disaccharide
  • a mass line may be generated by uniquely assigning a particular mass to a particular length of a given fragment (all possible di, tetra, hexa, octa, up to a hexadecasaccharide), and tabulating the results (An Example is shown in Figure 8).
  • mass spectrometry data indicates the mass of a fragment to 1 D accuracy
  • a length may be assigned uniquely to fragment by looking up a mass on the mass line. Further, it may be determined from the mass line that, within a fragment of particular length higher than a disaccharide, there is a minimum of 4.02D different in masses indicating that two acetate groups (84.08D) replaced a sulfate group (80.06D). Therefore, a number of sulfates and acetates of a polymer fragment may be determined from the mass from the mass spectrometry data and, such number may be assigned to the polymer fragment. In addition to molecular weight, other properties may be determined using methods known in the art.
  • compositional ratios of substituents or chemical units may be determined using methodology known in the art, such as capillary electrophoresis.
  • a polymer may be subjected to an experimental constraint such as enzymatic or chemical degradation to separate each of the chemical units of the polymers. These units then may be separated using capillary electrophoresis to determine the quantity and type of substituents or chemical units present in the polymer. Additionally, a number of substituents or chemical units can be determined using calculations based on the molecular weight of the polymer.
  • reaction samples may be analyzed by small-diameter, gel-filled capillaries.
  • the small diameter of the capillaries 50 ⁇ m allows for efficient dissipation of heat generated during electrophoresis.
  • high field strengths can be used without excessive Joule heating (400 V/m), lowering the separation time to about 20 minutes per reaction run, therefor increasing resolution over conventional gel electrophoresis.
  • many capillaries may be analyzed in parallel, allowing amplification of generated polymer information.
  • compositional analysis also may be used to determine a presence and composition of an impurity as well as a main property of the polymer.
  • Such determinations may be accomplished if the impurity does not contain an identical composition as the polymer.
  • To determine whether an impurity is present may involve accurately integrating an area under each peak that appears in the electrophoretogram and normalizing the peaks to the smallest of the major peaks. The sum of the normalized peaks should be equal to one or close to being equal to one. If it is not, then one or more impurities are present. Impurities even may be detected in unknown samples if at least one of the disaccharide units of the impurity differs from any disaccharide unit of the unknown. If an impurity is present, one or more aspects of a composition of the components may be determined using capillary electrophoresis.
  • compositions involve determining the composition of the major AT-III binding HLGAG decasaccharide ( + DDD4-7) and its minor contaminant (+ D5D4-7) present in solution in a 9:1 ratio.
  • Complete digestion of this 9:1 mixture with a heparinases yields 4 peaks: three representative of the major decasaccharide (viz., D, 4, and -7) which are also present in the contaminant and one peak, 5, that is present only in the contaminant.
  • the area of each peak for D, 4, and -7 represents an additive combination of a contribution from the major decasaccharide and the contribution from the contaminant, whereas the peak for 5 represents only the contaminant.
  • the area under the 5 peak may be used as a starting point. This area represents an area under the peak for one disaccharide unit of the contaminant. Subtracting this area from the total area of 4 and -7 and subtracted twice this area from an area under D yields a 1 : 1 :3 ratio of 4:-7:D. Such a ratio confirms the composition of the major component and indicates that the composition of the impurity is two Ds, one 4, one -7 and one 5.
  • hydrophobicity may be determined using reverse-phase high-pressure liquid chromatography (RP-HPLC).
  • Enzymatic sensitivity may be identified by exposing the polymer to an enzyme and determining a number of fragments present after such exposure. The chirality may be determined using circular dichroism. Protein binding sites may be determined by mass spectrometry, isothermal calorimetry and NMR.
  • Enzymatic modification (not degradation) may be determined in a similar manner as enzymatic degradation, i.e., by exposing a substrate to the enzyme and using MALDI- MS to determine if the substrate is modified.
  • a sulfotransferase may transfer a sulfate group to an HS chain having a concomitant increase in 80Da.
  • Conformation may be determined by modeling and nuclear magnetic resonance (NMR).
  • the relative amounts of sulfation may be determined by compositional analysis or approximately determined by raman spectroscopy.
  • the invention is useful for generating, searching and manipulating information about polymers.
  • the complete building block of a polymer is assigned a unique numeric identifier, which may be used to classify the complete building block.
  • each numeric identifier would represent a complete building block of a polysaccharide, including the exact chemical structure as defined by the basic building block of a polysaccharide and all of its substituents. charges etc.
  • a basic building block refers to a basic structure of the polymer unit e.g., a basic ring structure of a polysaccharide, such as iduronic acid or glucuronic acid but does not include substituents, charges etc.
  • the information is generated and processed in the same manner as described above with respect to "properties" of polymers.
  • this detection will be powerful.
  • the human sulfotransferases may be used to label specifically a certain residue. This will give additional structural information.
  • Nitrous acid degraded fragments unlike heparinase-derived fragments, do not have a UV-absorbing chromophore. As we have shown, MALDI-MS will record the mass of heparin fragments regardless of how they are derived.
  • two methods may be used to monitor fragments that lack a suitable chromophore. First is indirect detection of fragments. We may detect heparin fragments with our CE methodology using a suitable background absorber, e.g., 1,5-napthalenedisulfonic acid. The second method for detection involves chelation of metal ions by saccharides. The saccharide- metal complexes may be detected using UV-Vis just like monitoring the unsaturated double bond.
  • tags we may distinguish the reducing end of a glycosaminoglycan from the non-reducing end. All of these tags involve selective chemistry with the anomeric OH (present at the reducing end of the polymer), thus labeling occurs at the reducing end of the chain.
  • 2-aminobenzoic acid which is fluorescent.
  • tags involve chemistry of the following types: (1) reaction of amines with the anomeric position to form imines (i.e., 2-aminobenzoic acid), hydrazine reaction to form hydrazones, and reaction of semicarbazones with the anomeric OH to form semicarbazides.
  • Commonly used tags include the following compounds:
  • Girard's P reagent 3. Girard ' s T reagent
  • FIG. 2D illustrates an example of the chemical unit ID 204a.
  • ID 204a contains one or more fields 212a-e for storing information about properties of a polymer.
  • the invention encompasses all polymers, the use of the invention is described in more detail with respect to polysaccharides because of the complex nature of polysaccharides. The invention, however, is not limited to polysaccharides.
  • the heterogeneity of the heparin-like-glycosaminoglycan (HLGAG) fragments and the high degree of variability in their saccharide building blocks have hindered the attempts to sequence these complex molecules.
  • HLGAGs Heparin-like-glycosaminoglycans
  • HLGAGs which include heparin and heparan sulfate are complex polysaccharide molecules made up of disaccharide repeat units comprising hexoseamine and glucuronic/iduronic acid that are linked by ⁇ / ⁇ 1-4 glycosidic linkages. These defining units may be modified by: sulfation at the N, 3-0 and 6-0 position of the hexoseamine, 2-0 sulfation of the uronic acid, and C5 epimerization that converts the glucuronic acid to iduronic acid.
  • the disaccharide unit of HLGAG may be represented as:
  • the fields 212a-e may store any kinds of values, such as, for example single-bit values, single-digit hexadecimal values, or decimal values.
  • the chemical unit ID 204a includes each of the following fields: (1) a field 212a for storing a value indicating whether the polymer contains an iduronic or a glucuronic acid (I/G); (2) a field 212b for storing a value indicating whether the 2X position of the iduronic or glucuronic acid is sulfated or unsulfated; (3) a field 212c for storing a value indicating whether the hexoseamine is sulfated or unsulfated; (4) a field 212d indicating whether the 3X position of the hexoseamine is sulfated or unsulfated; and (5) a field 212e indicating whether the NX position of the hexoseamine is sulfated or acetylated.
  • each of the fields 212a-e may be represented as a single bit.
  • Table 2 illustrates an example of a data structure having a plurality of entries, where each entry represents an HLGAG encoded in accordance with Fig. 2D.
  • Bit values for each of the fields 212a-e may be assigned in any known manner. For example, with respect to field 212a (I/G), a value of one may indicate Iduronic and a value of zero may indicate Glucuronic, or vice versa.
  • Representing a HLGAG using a bit field may have a number of advantages. Because a property of an HLGAG may have one of two possible states, a binary bit is ideally-suited for storing information representing an HLGAG property. Bit fields may be used to store such information in a computer readable medium (e.g., a computer memory or storage device), for example, by packing multiple bits (representing multiple fields) into a single byte or sequence of bytes. Furthermore, bit fields may be stored and manipulated quickly and efficiently by digital computer processors, which typically store information using bits and which typically can quickly perform operations (e.g., shift, AND, OR) on bits. For example, as described in more detail below, a plurality of properties each stored as a bit field can be searched more quickly than searches conducted using typical character-based searching methods.
  • a plurality of properties each stored as a bit field can be searched more quickly than searches conducted using typical character-based searching methods.
  • bit fields to represent properties of HLGAGs permits a user to more easily incorporate additional properties (e.g., 4-0 sulfation vs. unsulfation) into a chemical unit ID 204a by adding extra bits to represent the additional properties.
  • the four fields 212b-e may be represented as a single hexadecimal (base 16) number where each of the fields 212a-e represents one bit of the hexadecimal number.
  • the five fields 212a-e of the record 210 may be represented as signed hexadecimal digit, in which the fields 212b-212e collectively encode a single-digit hexadecimal number as described above and the I/G field is used as a sign bit.
  • the hexadecimal numbers 0-F may be used to code chemical units containing iduronic acid and the hexadecimal numbers -0 to -F may be used to code units containing glucuronic acid.
  • the chemical unit ID 204a may, however, be encoded using other forms of representations, such as by using a twos-complement representation.
  • the fields 212a-e of the chemical unit ID 204a may be arranged in any order.
  • a gray code system may be used to code HLGAGs.
  • each successive value differs from the previous value only in a single bit position.
  • the values representing HLGAGs may be arranged so that any two neighboring values differ in the value of only one property.
  • Table 3 An example of a gray code system used to code HLGAGs is shown in Table 3.
  • Table 3 illustrates that use of a gray coding scheme arranges the disaccharide building blocks such that neighboring table entries differ from each other only in the value of a single property.
  • bit weights of 8, 4, 2, and 1 are used to calculate the numerical equivalent of a hexadecimal number with the most significant bit (I/G) being used as a sign bit.
  • weights of each of the fields 212a-e may be changed thereby implementing an alternative weighting system.
  • bit fields 212a-e may have weights of 16, 8, 4, -2, and -1, respectively, as shown in Table 4.
  • Modifying the weights of the bits may be used to score the disaccharide units. For example, a database of sequences may be created and the different disaccharide units may be scored based on their relative abundance in the sequences present in the database.
  • Some units for example, 6S I-H NAC . 3S , which rarely occur in naturally-occurring HLGAGs, may receive a low score based on a scheme in which the bits are weighted in the manner shown in Table 4.
  • the sulfation and acetylation positions may be arranged in an shown in Table 2: I/G, 2X, 6X, 3X, NX. These positions may, however, be arranged differently, resulting in a same set of codes representing different disaccharide units.
  • Table 5 shows an arrangement in which the positions are arranged as I/G, 2X, NX, 3X, 6X.
  • disaccharide units in some HLGAG sequences are neither N-sulfated nor N-acetylated.
  • Such disaccharide units may be represented using the chemical unit ID 204a in any of a number of ways.
  • disaccharide units that contain a free amine in the N position may be represented by, for example, adding an additional bit field.
  • an additional field NY may be used in the chemical unit ID 204a.
  • an NY field having a value of zero may correspond to a free amine
  • an NY field having a value of one may correspond to N-acetylation, or vice versa.
  • a value of one in the NX field 212e may correspond to N-sulfation.
  • disaccharide units that contain a free amine in the N position may be represented using a tristate field.
  • the field 212e (NX) in the chemical unit ID 204a may be a tristate field having three permissible values.
  • a value of zero may correspond to a free amine
  • a value of one may correspond to N-acetylation
  • a value of two could correspond to N-sulfation.
  • the values of any of the fields 212a-e may be represented using a number system with a base higher than two. For example, if the value of the field 212e (NX) is represented by a single-digit number having a base of three, then the field 212e may store three permissible values.
  • user may perform a query on the polymer database 102 to search for particular information.
  • a user may search the polymer database 102 for specified polymers, specified chemical units, or polymers or chemical units having specified properties.
  • a user may provide to a query user interface 108 user input 106 indicating properties for which to search.
  • the user input 106 may, for example, indicate one or more chemical units, a polymer of chemical units or one or more properties to search for using, for example, a standard character-based notation.
  • the query user interface 108 may, for example, provide a graphical user interface (GUI) which allows the user to select from a list of properties using an input device such as a keyboard or a mouse.
  • GUI graphical user interface
  • the query user interface 108 may generate a search query 110 based on the user input 106.
  • a search engine 112 may receive the search query 110 and generate a mask 114 based on the search query.
  • Example formats of the mask 114, and example techniques to determine whether properties specified by the mask 114 match properties of polymers in the polymer database 102 are described in more detail below in connection to Fig. 3.
  • the search engine 112 may determine whether properties specified by the mask 114 match properties of polymers stored in the polymer database 102. Subsequently, the search engine 112 may generate search results 116 based on the search indicating whether the polymer database 102 includes polymers having the properties specified by the mask 114.
  • the search results 116 also may indicate polymers in the polymer database 102 that have the properties specified by the mask 114. For example, if the user input 106 specified properties of a chemical unit, the search results 116 may indicate which polymers in the polymer database 102 include the specified chemical unit. Alternatively, if the user input 106 specified particular chemical unit properties, the search results 116 may indicate polymers in the polymer database 102 that include chemical units having the specified chemical unit properties.
  • Fig. 3 is a flowchart illustrating an example of a process 300 that may be used by the search engine 112 to generate the search results 116.
  • the search engine 112 may receive a search query 110 from the query user interface 108.
  • the search engine 1 12 may generate a mask 114 generated based on the search query 110.
  • the search engine 112 may perform a binary operation on one or more of the records 104a- ⁇ in the polymer database 102 by applying the mask 114.
  • the search engine 112 may generate the search results 1 16 based on the results of the binary operation performed in step 306.
  • the received search query 110 may indicate to search the polymer database 102 for a particular chemical unit, e.g. the chemical unit - S -H NS - If , for example, the coding scheme shown in Table 1 is used to encode chemical units in the polymer database, the chemical unit I 2S -H NS may be represented by a binary value of 01001.
  • the search engine 112 may use the binary value of the chemical unit, i.e., 01001, as the value of the mask 114.
  • the values of the bits of the mask 114 may specify the properties of the chemical unit I 2S - H N s.
  • the value of zero in the leftmost bit position may indicate Iduronic, and the value of one in the next bit position may indicate that the 2X position is sulfated.
  • the search engine 112 may use this mask 114 to determine whether polymers in the polymer database 102 contain the chemical unit l2s-H NS . To make this determination, the search engine 112 may perform a binary operation on the data units 104a- « of the polymer database 102 using the mask 114 (step 306).
  • the search engine 112 may perform a logical AND operation on each chemical unit of each of the polymers in the polymer database 102 using the mask 114. If the result of the logical AND operation on a particular chemical unit is equal to the value of the mask 114, then the chemical unit may satisfy the search query 110, and, in act 308, the search engine 112 may indicate a successful match in the search results 116. The search engine 112 may generate additional information in the search results 116, such as the polymer identifier of the polymer containing the matching chemical unit.
  • the search engine 112 In response to receiving the search query in act 302, in act 304, the search engine 112 also may generate the mask 1 14 that indicates one or more properties of a particular polymer or chemical unit. To generate the mask 114 for such a search query, the search engine 112 may set each bit position in the mask according to a property specified by the search query to the value specified by the search query.
  • search query 110 that indicates a search for all chemical units in which both the 2X position and the 6X position are sulfated.
  • the search engine 1 12 may set the bit positions of the mask corresponding to the 2X and 6X positions to a value corresponding to being sulfated.
  • the mask corresponding to this search query is 01100.
  • the two bits of this mask that have a value of one correspond to the bit positions in Table 1 corresponding to the 2X and 6X positions.
  • the search engine 112 may perform a logical AND operation on the chemical unit identifier of the chemical unit in the polymer database 102 using the mask 114. To generate search results for this chemical unit (i.e., act 308), the search engine 112 may compare the result of the logical AND operation to the mask 114. If the values of the bit positions of the logical AND operation corresponding to the properties specified by the search query are equal to the values of the same bit positions of the mask 114, then the chemical unit has the properties specified by the search query 110, and the search engine 112 indicates a successful match in the search results 116.
  • the search engine 112 compares bit positions 3 and 2 of the result of the logical AND operation to bit positions 3 and 2 of the mask. If the values in both bit positions are equal, then the chemical unit has the properties specified by the mask 114.
  • the techniques described above for generating the mask 114 and searching with a mask 114 also may be used to perform searches with respect to sequences of chemical units or entire polymers.
  • the search engine 112 may fill the mask 114 with a sequence of bits corresponding to the concatenation of the binary encodings of the specified sequence of chemical units. The search engine 112 may then perform a binary AND operation on the polymer identifiers in the polymer database 102 using the mask 114, and generate the search results 116 as described above.
  • the techniques described above for generating the mask 1 14 and searching with the mask 1 14 are provided merely as an example. Other techniques for generating and searching with the mask 114 may also be used.
  • the search engine 112 also may use more than one mask for each search query 110, and the search engine 112 may perform multiple binary operations in parallel in order to improve computational efficiency.
  • binary operations other than a logical AND may be used to determine whether properties of the polymers in the polymer database 102 match the properties specified by the mask 114.
  • Other binary operations include, for example, logical OR and logical XOR (exclusive or). Such binary operations may be used alone or in combination with each other.
  • the polymer database 102 may be searched quickly for particular chemical units.
  • One advantage of the process 300, if used in conjunction with a chemical unit coding scheme that encodes properties of chemical units using binary values is that a chemical unit identifier (e.g., the chemical unit identifier 204a) may be compared to a search query (in the form of a mask) using a single binary operation (e.g., a binary AND operation).
  • the speed of the techniques described above for searching binary operations may be constant in relation to the length of a sub-sequence that is the basis for the search query.
  • the search engine 112 can search for a query sequence of chemical units using a single binary operation (e.g., a logical AND operation) regardless of the length of the query sequence, searches may be performed more quickly than conventional character-based methods whose speed is related to the length of the query sequence.
  • the binary operations used by the search engine 1 12 may be performed more quickly because conventional computer processors are designed to perform binary operations on binary data.
  • a further advantage of the techniques described above for searching using binary operations is that encoding one or more properties of a polymer into the notational representation of the polymer enables the search engine 112 to quickly and directly search the polymer database 102 for particular properties of polymers. Because the properties of a polymer are encoded into the polymer's notational representation, the search engine 112 may determine whether the polymer has a specified property by determining whether the specified property is encoded in the polymer's notational representation. For example, as described above, the search engine 112 may determine whether the polymer has the specified property by performing a logical AND operation on the polymer's notational representation using the mask 114. This operation may be performed quickly by conventional computer processors and may be performed using only the polymer's notational representation and the mask, without reference to additional information about the properties of the polymer.
  • complete building block of a polymer may be assigned a unique numeric identifier, which may be used to classify the complete building block.
  • each numeric identifier may represent a complete building block of a polysaccharide, including the exact chemical structure as defined by the basic building block of a polysaccharide and all of its substituents, charges etc.
  • a basic building block refers to a basic ring structure such as iduronic acid or glucuronic acid but does not include substituents, charges etc.
  • a computer system that may implement the system 100 of FIG. 1 as a computer program typically may include a main unit connected to both an output device which displays information to a user and an input device which receives input from a user.
  • the main unit generally includes a processor connected to a memory system via an interconnection mechanism.
  • the input device and output device also may be connected to the processor and memory system via the interconnection mechanism.
  • Example output devices include a cathode ray tube (CRT) display, liquid crystal displays (LCD), printers, communication devices such as a modem, and audio output.
  • Example input devices also may be connected to the computer system.
  • Example input devices include a keyboard, keypad, track ball, mouse, pen and tablet, communication device, and data input devices such as sensors. The subject matter disclosed herein is not limited to the particular input or output devices used in combination with the computer system or to those described herein.
  • the computer system may be a general purpose computer system which is programmable using a computer programming language, such as C++, Java, or other language, such as a scripting language or assembly language.
  • the computer system also may include specially-programmed, special purpose hardware such as, for example, an Application- Specific Integrated Circuit (ASIC).
  • ASIC Application- Specific Integrated Circuit
  • the processor typically is a commercially-available processor, of which the series x86, Celeron, and Pentium processors, available from Intel, and similar devices from AMD and Cyrix, the 680X0 series microprocessors available from Motorola, the PowerPC microprocessor from IBM and the Alpha-series processors from Digital Equipment Corporation, are examples. Many other processors are available.
  • Such a microprocessor executes a program called an operating system, of which Windows NT, Linux, UNIX, DOS, VMS and OS8 are examples, which controls the execution of other computer programs and provides scheduling, debugging, input/output control, accounting, compilation, storage assignment, data management and memory management, and communication control and related services.
  • the processor and operating system define a computer platform for which application programs in high-level programming languages may be written.
  • a memory system typically includes a computer readable and writeable nonvolatile recording medium, of which a magnetic disk, a flash memory and tape are examples.
  • the disk may be removable, such as a "floppy disk,” or permanent, known as a hard drive.
  • a disk has a number of tracks in which signals are stored, typically in binary form, i.e., a form interpreted as a sequence of one and zeros. Such signals may define an application program to be executed by the microprocessor, or information stored on the disk to be processed by the application program.
  • the processor causes data to be read from the nonvolatile recording medium into an integrated circuit memory element, which is typically a volatile, random access memory such as a dynamic random access memory (DRAM) or static memory (SRAM).
  • DRAM dynamic random access memory
  • SRAM static memory
  • the integrated circuit memory element typically allows for faster access to the information by the processor than does the disk.
  • the processor generally manipulates the data within the integrated circuit memory and then copies the data to the disk after processing is completed.
  • a variety of mechanisms are known for managing data movement between the disk and the integrated circuit memory element, and the subject matter disclosed herein is not limited to such mechanisms. Further, the subject matter disclosed herein is not limited to a particular memory system.
  • the subject matter disclosed herein is not limited to a particular computer platform, particular processor, or particular high-level programming language. Additionally, the computer system may be a multiprocessor computer system or may include multiple computers connected over a computer network. It should be understood that each module (e.g. 110, 120) in FIG. 1 may be separate modules of a computer program, or may be separate computer programs. Such modules may be operable on separate computers. Data (e.g., 104, 106, 110, 114 and 116) may be stored in a memory system or transmitted between computer systems. The subject matter disclosed herein is not limited to any particular implementation using software or hardware or firmware, or any combination thereof.
  • the various elements of the system may be implemented as a computer program product tangibly embodied in a machine-readable storage device for execution by a computer processor.
  • Various steps of the process may be performed by a computer processor executing a program tangibly embodied on a computer-readable medium to perform functions by operating on input and generating output.
  • Computer programming languages suitable for implementing such a system include procedural programming languages, object-oriented programming languages, and combinations of the two.
  • the system 400 includes a polymer database 402 which includes a plurality of records storing information corresponding to a plurality of polymers. Each of the records may store information about properties of the corresponding polymer, properties of the corresponding polymer's constituent chemical units, or both.
  • the polymers for which information is stored in the polymer database 402 may be any kind of polymers.
  • the polymers may include polysaccharides, nucleic acids, or polypeptides.
  • each of the records in the polymer database 402 includes a polymer identifier (ID) that identifies the polymer corresponding to the record.
  • ID polymer identifier
  • the record also includes chemical unit identifiers (IDs) corresponding to chemical units that are constituents of the polymer corresponding to the record.
  • IDs chemical unit identifiers
  • Polymers may be represented in the polymer database in other ways.
  • records in the polymer database 402 may include only a polymer ID or may only include chemical unit IDs.
  • the polymer database 402 may be any kind of storage medium capable of storing information about polymers as described herein.
  • the polymer database 402 may be a flat file, a relational database, a table in a database, an object or structure in a computer-readable volatile or non-volatile memory, or any data accessible to a computer program, such as data stored in a resource fork of an application program file on a computer-readable storage medium.
  • a polymer ID includes a plurality of fields for storing information about properties of the polymer corresponding to the record containing the polymer ID.
  • chemical unit IDs include a plurality of fields for storing information about properties of the chemical unit corresponding to the chemical unit ID.
  • the fields of chemical unit IDs may store any kind of value that is capable of being stored in a computer readable medium, such as a binary value, a hexadecimal value, an integral decimal value, or a floating point value.
  • the fields may store information about any properties of the corresponding chemical unit.
  • a compositional analyzer 408 receives as input a sample polymer 406 and generates as output polymer composition data 410 that is descriptive of the composition of the sample polymer.
  • a compositional analyzer as used herein is any type of equipment or experimental procedure that may be used to identify a property of a polymer modified by an experiment constraint, such as those described above. These include, for instance, but are not limited to capillary electrophoresis, mass spectrometry, and chromatography.
  • the polymer composition data 410 includes information about the sample polymer 406, such as the properties of the chemical units in the sample polymer 406 and the number of chemical units in the sample polymer 406.
  • a sequencer 412 generates a candidate list 416 of a subpopulation of polymers that might match the sample polymer 406 in the process of sequencing the sample polymer 406 using information contained in a mass line 414 and the polymer database 402.
  • a candidate list is also referred to herein as a "population" of polymers.
  • the candidate list 416 contains zero or more polymers that correspond to the sample polymer 406.
  • a subpopulation of polymers is defined as a set of polymers having at least two properties in common with a sample polymer. It is useful to identify subpopulations of polymers in order to have an information set with which to compare the sample polymer 406.
  • the sequence DD7DAD-7 which is a tetradecasaccharide
  • the compositional analyzer 408 may, for example, perform compositional analysis of DD7DAD-7 by degrading the sequence to its disaccharide building blocks and analyzing the relative abundance of each unit using capillary electrophoresis to generate the polymer composition data 410.
  • the polymer composition data 410 in this case would show a major peak corresponding to ⁇ D, a peak about l A the size of the major peak corresponding to ⁇ 7 and another peak about 1/4 the size of the major peak corresponding to ⁇ A.
  • the ⁇ sign is used because degradation by heparinase would create a double bond between the C4 and C5 atoms in the uronic acid ring thereby leading to the loss of the iduronic vs. glucuronic acid information. From the polymer composition data 410, it may be inferred that there are 4 ⁇ Ds, 2 ⁇ 7s and a ⁇ A in the sequence.
  • a process 500 that may be performed by the sequencer 412 to sequence the sample polymer 406 is shown.
  • the sequencer 412 receives the polymer composition data 410 from the compositional analyzer 408.
  • the sequencer 412 uses the polymer composition data 410 and the information contained in the polymer database 402 to generate an initial candidate list 416 of all possible polymers: (1) having the same length as the sample polymer 406 and (2) having the same constituent chemical units as the sample polymer 406 (step 504).
  • step 504 generation of the candidate list 416) involves generating all possible sequences having the same length as the sample polymer 406 and having 4 ⁇ Ds, 2 ⁇ 7s and a ⁇ A.
  • the sequencer 412 uses a brute force method to generate all sequences having these characteristics by generating all sequences of length seven having 4 ⁇ Ds, 2 ⁇ 7s and a ⁇ A using standard combinatoric methods.
  • the sequencer 412 uses the data from the mass line 414 to progressively eliminate sequences from the list generated in step 504 until the number of sequences in the list reaches a predetermined threshold (e.g., one). To perform such elimination, in one embodiment, the sequencer 412 calculates the value of a predetermined property of each of the polymers in the candidate list 416 (step 506).
  • the predetermined property may, for example, be the mass of the polymer. An example method for calculating the mass of a polymer will be described in more detail below.
  • the sequencer 412 compares the calculated values of the predetermined property of the polymers in the candidate list 416 to the value of the predetermined property of the sample polymer 406 (step 508).
  • the sequencer 412 eliminates candidate polymers from the candidate list 416 whose predetermined property values do not match the value of the predetermined property of the sample polymer 406 within a predetermined range (step 508).
  • the predetermined property is molecular weight
  • the predetermined range may be ⁇ 1.5D.
  • the sequencer 412 applies an experimental constraint to the sample polymer 406 to modify the sample polymer 406 (step 510).
  • An "experimental constraint" as used herein is a biochemical process performed on a polymer which results in modification to the polymer which may be detected.
  • Experimental constraints include but are not limited to enzymatic digestion, e.g., with an exoenzyme, an endoenzyme, a restriction endonuclease; chemical digestion; chemical modification; interaction with a binding compound; chemical peeling (i.e., removal of a monosaccharide unit); and enzymatic modification, for instance sulfation at a particular position with a heparan sulfate sulfotransferases.
  • the sequencer 412 measures properties of the modified sample polymer 406 (step 512).
  • the sequencer 412 eliminates from the candidate list 416 those candidate polymers having property values that do not match the property values of the experimental results 422 (step 514). If the size of the candidate list 416 is less than a predetermined threshold (e.g., 1)
  • step 516 then the sequencer 412 is done (step 518).
  • the contents of the candidate list 416 at this time represent the results of the sequencing process.
  • the candidate list 416 may contain zero or more polymers, depending upon the contents of the polymer database 402 and the value of the predetermined threshold. If the size of the candidate list 416 is not less than the predetermined threshold (step 516), steps 510-516 are repeated until the size of the candidate list 416 falls below the predetermined threshold.
  • the sequencer 412 may, for example, display the candidate list 416 to the user on an output device such as a computer monitor.
  • the sequencer 412 uses a genetic algorithm process 600 to generate the initial candidate list 416 and to modify the candidate list 416 in order to arrive at a final candidate polymer that identifies the sequence of the sample polymer 406.
  • the sequencer 412 generates a population of random sequences with the composition indicated by the polymer composition data 410 and having the same length as the sample polymer 406 (step 602).
  • the sequencer 412 evaluates the fitness (score) of the polymers in the candidate list 416 using a scoring function based on the enzymatic degradation of enzyme ENZ (step 604).
  • the genetic algorithm process 600 uses the fitness values to decide which of the sequences in the candidate list 416 can survive into the next generation and which of the sequences in the candidate list 416 has the highest chance of producing other sequences of equal or higher fitness by cross-over and mutation.
  • the sequencer 412 then performs cross-over and mutation operations that select for fit sequences in the candidate list 416 into the next generation (step 606). If at least a predetermined number (e.g., three) of generations of the candidate list 416 include copies of the correct sequence with the maximum fitness (step 608), then the sequencer 412 is done sequencing. Otherwise, the sequencer 412 repeats steps 604-606 until the condition of step 608 is satisfied.
  • Cross-over and mutation operations are used by genetic algorithms to randomly sample the different regions of a search space.
  • steps 510 and 512 are automated (e.g., carried out by a computer).
  • the sequencer 412 may divide the candidate list 416 into categories (the categories are preferably based on properties), such as hepl cleavable, hepIII cleavable, and nitrous acid cleavable (the property is enzymatic sensitivity).
  • the sequencer 412 may then simulate the corresponding degradation or modification of the sequences present in each of the categories and search for those sequences that give fragments of unique masses.
  • the sequencer 412 chooses the particular enzyme or chemical as the experimental constraint to eliminate candidate polymers from the candidate list 416 (step x).
  • the particular enzyme or chemical as the experimental constraint to eliminate candidate polymers from the candidate list 416 (step x).
  • hepl, hepIII, and nitrous acid are used, other experimental constraints such as enzymes may be used including the exoenzymes and other HLGAG degrading chemicals.
  • the "constraints used for convergence" column indicates constraints that have been shown empirically to achieve convergence for the corresponding known sequence.
  • Table 6 demonstrates that the presence of f(G) and f(H NAc ) are important factors in the decision to use hepIII and nitrous acid, because nitrous acid clips after a H NS , and hepIII clips after a disaccharide unit containing G.
  • the disaccharide unit I 2S -H S,6 S is the dominant unit in heparin-like regions (i.e., highly-sulfated regions) of the HLGAG chains. Therefore, if a sequence is more heparin-like, then hepl may be chosen as the default enzyme and the information content present in chemical units containing G and H NAC become important for choosing enzymes and chemicals other than hepl.
  • hepIII may be a default enzyme and f(l2s) and f(HNs) become important for choosing hepl and nitrous acid.
  • one may also calculate the positional sulfate or acetate distribution along the chain and generate the criterion for using the sulfotransferases or sulfateases for convergence.
  • the polymer database 402 may include information indicating that sulfation at a position of a polymer contributes 80.06D to the mass of the polymer and that substitution of a sulfate for an acetate contributes an additional 38.02D to the mass of the polymer. Therefore, the mass M of any polymer in the polymer database 402 may be calculated using the following formula:
  • M 379.33 + [0 80.06 80.06 80.06 38.02] * C, where C is the vector containing the binary representation of the polymer and * is a vector multiplication operator.
  • C the vector containing the binary representation of the polymer
  • * is a vector multiplication operator.
  • HLGAG fragments may be degraded using enzymes such as heparin lyase enzymes or nitrous acid and they may also be modified using different enzymes that transfer sulfate groups to the positions mentioned earlier or remove the sulfate groups from those positions.
  • the modifying enzymes are exolytic and non-processive which means that they just act once on the non reducing end and will let go of the heparin chain without sequentially modifying the rest of the chain. For each of the modifiable positions in the disaccharide unit there exits a modifying enzyme.
  • the modifying enzymes include 2-0 sulfatase/ sulfotransferase, 3-0 sulfatase/sulfotransferase, 6-0 sulfatase/sulfotransferase and N-deacetylase-N- sulfotransferase.
  • HLGAG degrading enzymes include heparinase-I, heparinase- II , heparinase-III,
  • D-glucuronidase and L-iduronidase The heparinases cleave at the glycosidic linkage before a uronic acid.
  • Heparinase I clips at a glycosidic linkage before a 2 -O sulfated iduronic acid.
  • Heparinase -III cleaves at a glycosidic linkage before an unsulfated glucuronic acid.
  • Heparinase -II cleaves at both Hep-I and Hep-III cleavable sites. After cleavage by the heparinases the uronic acid before which the cleavage occurs loses the information of iduronic vs. glucuronic acid because a double bond is created between the C4 and C5 atoms of the uronic acid.
  • Glucuronidase and iduronidase as their name suggests cleave at the glycosidic linkage after a glucuronic acid and iduronic acid respectively.
  • Nitrous acid clips randomly at glycosidic linkages after a N-sulfated hexosamine and converts the six membered hexosamine ring to a 5 membered anhydromannitol ring.
  • the above rules for the enzymes may easily be encoded into a computer as described above using binary arithmetic so that the activity of an enzyme on a sequence may be carried out using simple binary operators to give the fragments that would be formed from the enzymatic activity.
  • the invention is a database of polysaccharide sequences, as well as, motif search and sequence alignment algorithms for obtaining valuable information about the nature of polysaccharide-protein interactions that are vital for the biological functioning of these molecules.
  • sequence information in the database of polysaccharide sequences may also be used to provide valuable insight into sequence- structure relationships of these molecules.
  • the methods of the invention may be used for any purpose in which it is desirable to identify structural properties related to a polymer.
  • the methods of the invention may be used for analysis of low molecular weight heparin.
  • LMWH low molecular weight heparin.
  • CE and MALDI-MS we may obtain an "digest spectrum" of various preparations of LMWH, thus deriving information about the composition and variations thereof. Such information is of value in terms of quality control for LMWH preparations.
  • HLGAG expression can be as a function both of position and of time in Drosophila development.
  • the methods may be used as a diagnostic tool for human diseases.
  • MPS mucopolysaccharidosis
  • the molecular basis for these diseases is mostly in the degradation pathway for HLGAGs.
  • mucopolysaccharidosis type I involves a defect in iduronidase, which clips unsulfated iduronate residues from HLGAG chains.
  • MPS II mucopolysaccharidosis type II
  • the methods of the invention are useful for mapping protein binding HLGAG sequences.
  • the MALDI-MS sequencing approach may be used to specifically map HLGAG sequences that bind to selected proteins. This is achieved by sequencing the HLGAG chain in the presence of a target protein as well as in the absence of the particular protein. In this manner, sequences protected from digestion are indicative of sequences that bind with high affinity to the target protein.
  • the methods of the invention may be used to analyze branched or unbranched polymers. Analysis of branched polymers is more difficult than analysis of unbranched polymers because branched carbohydrates, are "information dense" molecules.
  • Branched polysaccharides include a few building blocks that can be combined in several different ways, thereby, coding for many sequences. For instance, a trisaccharide, in theory, can give rise to over 6 million different sequences.
  • the methods for analyzing branched polysaccharides are advanced by the creation of an efficient nomenclature that is amenable to computational manipulation.
  • an efficient nomenclature for branched sugars that is amenable to computational manipulation has been developed according to the invention.
  • Two types of numerical schemes that may encode the sequence information of these polysaccharides has been developed in order to bridge the widely used graphic (pictorial) representation and the proposed numerical scheme discussed below. a.
  • Byte-based (Binary-scheme) notation scheme The first notation scheme is based on a binary numerical system. The binary representation in conjunction with a tree-traversing algorithm is used to represent all the possible combinations of the branched polysaccharides. The nodes (branch points) are easily amenable to computational searching through tree-traversing algorithms (Figure 7A).
  • Figure 7 A shows a notation scheme for branched sugars. Each monosaccharide unit can be represented as a node (N) in a tree.
  • the building blocks can be defined as either (A), (B), or (C) where Nl, N2, N3, and N4 are individual monosaccharides. Each of these combinations can be coded numerically to represent building blocks of information. By defining glycosylation patterns in this way, there are several tree traversal and searching algorithms in computer science that may be applied to solve this problem.
  • an N-linked glycosylation in vertebrates contains a core region (the tri-mannosyl chitobiose moiety), and up to four branched chains from the core.
  • the notation scheme also includes other modification (such as addition of fucose to the core, or fucosylation of the GlcNac in the branches or sialic acid on the branches).
  • the superfamily of N-linked polysaccharides can be broadly represented by three modular units: a) core region: regular, fucosylated and/or bisected with a GlcNac, b) number of branches: up to four branched chains, each with GlcNac, Gal and Neu., and c) modifications of the branch sugars.
  • These modular units may be systematically combined to generate all possible combinations of the polysaccharide.
  • Representation of the branches and the sequences within the branches can be performed as a n-bit binary code (0 and 1) where n is the number of monosaccharides in the branch.
  • Figure 7C depicts a binary code containing the entire information regarding the branch.
  • each branch can be represented by a 3-bit binary code, giving a total of 12 binary bits.
  • the first bit represents the presence (binary 1) or absence (binary 0) of the GlcNac residue adjoining the mannose.
  • the second and the third bit similarly represent the presence or absence of the Gal and the Neu residues in the branch.
  • a complete chain containing GlcNac-Gal-Neu is represented as binary (11 1) which is equivalent to decimal 7.
  • Four of the branches can then be represented by a 4 bit decimal code, the 1 st bit of the decimal code for the first branch and the 2 nd , the second branch etc (right).
  • This simple binary code does not contain the information regarding the linkage ( ⁇ vs. ⁇ and the 1-6 or 1-3 etc.) to the core.
  • This type of notation scheme may be easily expanded to include additional bits for branch modification. For instance, the presence of a 2-6 branched neuraminic acid to the GlcNac in the branch can be encoded by a binary bit.
  • b. Prime Decimal Notation Scheme Similar to the binary notation described above, a second computationally friendly numerical system, which involves the use of a prime number scheme, has been developed. The algebra of prime numbers is extensively used in areas of encoding, cryptography and computational data manipulations. The scheme is based on the theorem that for small numbers, there exists a uniquely-definable set of prime divisors. In this way, composition information may be rapidly and accurately analyzed. This scheme is illustrated by the following example.
  • composition of a polysaccharide chain may then be represented as the product of the prime decimals that represent each of the building blocks.
  • GlcNac is assigned the number 3 and mannose the number 2.
  • the prime divisors are therefore unique and can encode the composition information. This becomes a problem when one gets to very large numbers but not an issue for the size of numbers we encounter in this analysis. From this number the mass of the polysaccharide chain can be determined.
  • the power of the computational approaches of the notional scheme may be used to systematically develop an exhaustive list of all possible combinations of the polysaccharide sequences. For instance, an unconstrained combinatorial list of possible sequences of size m n , where m is the number of building blocks and n is the number of positions in the chain may be used.
  • a combination of MALDI-MS and CE may be used, as shown in the Examples. Elimination of the pendant arms of the branched polysaccharide may be achieved by the judicious use of exo and endoenzymes. All antennary groups may be removed, retaining only the GlcNAc moieties extending from the mannose core and forming an "extended" core. In this way, information about branching is retained, but separation and identification of glycoforms is made simpler.
  • One methodology that could be employed to form extended cores for most polysaccharide structures is the following. Addition of sialidases, and fucosidases will remove capping and branching groups from the arms.
  • Example 1 Identification of the number of fragments versus the fragment mass for Di, Tetra, and Hexasaccharide.
  • the masses of all the possible disaccharide, tetrasaccharide and hexasaccharide fragments were calculated and are shown in the mass line shown in Figure 8.
  • the X axis shows the different possible masses of the di, tetra and hexasaccharides and the Y axis shows the number of fragments that having that particular mass. Although there is a considerable overlap between the tetra and hexasaccharide the minimum difference in their masses is 13.03D. Note that the Y axis has been broken to omit values between 17 and 40, to show all the bars clearly.
  • Example 2 Sequencing of an octasaccharide of HLGAG.
  • compositional analysis of O2 was completed by exhaustive digest of a 30 ⁇ M sample with heparinases I-III and analysis by capillary electrophoresis (CE). Briefly, to 10 ⁇ L of polysaccharide was added 200 nM of heparinases I-III in sodium phosphate buffer pH 7.0. The reaction was allowed to proceed at 30°C overnight. For CE analysis the sample was brought to 25 ⁇ L. Naphthalene trisulfonic acid (2 ⁇ M) was run as an internal standard. Assignments of ⁇ U 2 S-HNS,6S and ⁇ U-H N s, 6 s were made on the basis that they comigrated with known standards.
  • the CE data for 02 octasaccharide demonstrated that there is a major peak corresponding to the commonly occurring trisulfated disaccharide ( ⁇ U 2S -H NS,OS ) and a small peak that corresponds to a disulfated disaccharide ( ⁇ U-H NS,6S )-
  • the relative abundance of these disaccharide units obtained from the CE data shows that there are 3 Ds ( ⁇ ) and a 5 ( ⁇ ).
  • the number of possible combination of sequences having these disaccharide units is 32. The possible combinations are shown in Table 7 below.
  • Digestion of 02 with heparinase I Digestion of O2 was completed using both a short procedure and an exhaustive digest. "Short” digestion was defined as using 100 nM of heparinase I and a digestion time of 10 minutes. “Exhaustive” digestion was defined as overnight digestion with 200 nM enzyme. All digests were completed at room temperature. In the case of O2, both digest conditions yield the same results. Short digestion with heparinase I yields a pentasulfated tetrasaccharide (no acetyl groups) of m/z 5300J (1074.6) and a disaccharide of m/z 4802.6 (577J) corresponding to a trisulfated disaccharide. This profile did not change upon exhaustive digest of O2.
  • O2 Upon treatment with heparinase I, O2 is clipped to form fragments with m/z 4802.6 and 5,300.1. From the masses of these fragments it was possible to uniquely determine that m/z of 4802.6 corresponded to a trisulfated disaccharide and m/z of 5300J corresponded to a pentasulfated tetrasaccharide. Since the disaccharide composition of the sequence was known the only trisulfated disaccharide that may be formed is ⁇ D and the possible pentasulfated tetrasaccharides that may be formed are ⁇ 5D, ⁇ 5-D, ⁇ D5 and ⁇ D-5.
  • Table 7 provides a list of sequences that satisfy the product profiles of hepl and hepIII digests of the octasaccharide 02.
  • (a) shows the sequences that gave the di and tetrasaccharide fragments as observed from the mass spectrometry data.
  • the fragments listed below along with their masses are those generated by computer simulation of hepl digest
  • the fragments along with their masses were generated by computer simulation of hepIII digestion.
  • Heparinase III treatment of 02 resulted in a major fragment of m/z 5958.7 which was uniquely identified as a hexasaccharide with 9 sulfate groups.
  • the only sequence that satisfied the product profile of hepIII digestion was ⁇ DDD-5 which is shown in Table 7.
  • Table 7 shows that there should be a -5 (G- HNAC,6S ) in the reducing end. This was consistent with the rule used for hepIII digestion, i.e. hepIII clips before a G.
  • the masses shown in the table are integers. The masses used to search for the required fragments were accurate to two decimal places.
  • Example 3 Sequencing of a basic fibroblast growth factor (FGF-2) binding saccharide.
  • MALDI-MS of a basic fibroblast growth factor (FGF-2) binding saccharide was performed to determine the mass and size of the saccharide as a complex with FGF-2 (G. Venkataraman et al., PNAS. 96, 1892, (1999).;. Dimers of FGF-2 bound to the saccharide (S) yielding a species with a m/z of 37,009. By subtraction of FGF-2 molecular weight, the molecular mass of the saccharide was determined to be 2808, corresponding to a decasaccharide with 14 sulfates and an anhydromannitol at the reducing end. 1. Compositional Analysis:
  • compositional analysis and CE of FGF-2 binding saccharide were completed as described above. Compositional analysis of this sample resulted in two peaks corresponding to ⁇ D ( ⁇ U 2S HNS,6S) and ⁇ D' ( ⁇ U2sMan 6 s) in the ratio 3:1.
  • ⁇ D ⁇ U 2S HNS,6S
  • ⁇ D' ⁇ U2sMan 6 s
  • the non-reducing end residue was identified as +D (I2 S H S , OS ) by sequencing with exoenzymes.
  • the number of possible sequences with this composition is 16 Table 8(i). Of the 16 sequences, those that could result in the observed fragments upon heparinase I digestion of the decasaccharide are shown in Table 8(ii). 65521 53
  • the disaccharide unit at the non-reducing end was assigned to be a +D using exoenzymes and the anhydromannitol group at the reducing end is shown as '.
  • the mass of the fragments resulting from digestion of decasaccharide with heparinase I are shown in (ii). Also shown in (ii) are those sequences from (i) that satisfy heparinase I digestion data. Section (iii) of Table 8 shows the sequence of decasaccharide from (ii) that satisf i es the data from exhaustive digestion using heparinase I.
  • This product profile may be obtained only if there is a hepl cleavable site at every position in the decasaccharide which led us to converge to the final sequence DDDDD' shown in section iii of Table 14.
  • the above taken together confirm the sequence of the FGF-2 binding decasaccharide sequence to be DDDDD' [G 2 sHNs.6s)4l2sMan 6S ].
  • Example 4 Sequencing of an AT-III binding saccharide.
  • An AT-III binding saccharide was used as an example of the determination of a complex sequence.
  • compositional analysis and CE were completed as described above.
  • Compositional analysis of an AT-III binding saccharide indicated the presence of three building blocks, corresponding to ⁇ U 2S HNS.6S ( ⁇ D).
  • the shortest polysaccharide that may be formed with this composition corresponds to a decasaccharide. consistent with the MALDI-MS data.
  • the total number of possible combinations of this tridecasulfated single acetylated decasaccharide sequences with the above disaccharide building blocks is 320 Table 9.
  • the major fragments include a decasulfated singly-acetylated octasaccharide (m/z 6419.7), a heptasulfated, singly acetylated hexasaccharide with m/z 5842J, a hexasulfated tetrasaccharide with m/z of 5383J and a trisulfated disaccharide (m/z 4805.3). Also present is a contaminant (*). a pentasulfated tetrasaccharide.
  • the sequence of AT-III binding decasaccharide has been reported to be D4-7DD. on the basis of NMR spectroscopy (Y.Toida et al., j. Biol. Chem. 271, 32040 (1996)). Such a sequence should show the appearance of a tagged D or DD residue at the reducing end.
  • this saccharide did not contain an intact AT-III binding site, as proposed. Therefore, confirmation of the proposed sequence was sought through the use of integral glycan sequencing (IGS) methodology.
  • IGS integral glycan sequencing
  • a 'mass-tag' was used at the reducing end of the saccharide ( ⁇ m/z of 56J shown as 't'). This enabled the identification of the saccharide sequence close to and at the reducing end.
  • Typical yields for the mass-tag labeling varied between 80-90% as determined by CE.
  • the m/z value of 5320.9 and 5897.7 corresponded to a tagged tetrasulfated tetrasaccharide and a tagged heptasulfated hexasaccharide, both containing the N-acetyl glucosamine residue.
  • This result indicated that +/- 4 (I/GH NAC,OS ) is present at the reducing or one unit from the reducing end, thereby limiting the number of possible sequences from 28 to 6 Table 9 (iii).
  • Partial nitrous acid digestion of the tagged as well as the untagged decasaccharide provided no additional constraints but confirmed the heparinase II data. Exhaustive nitrous acid digestion, however, gave only the reducing end tetrasaccharide (with and without the tag) as an undipped product. Exhaustive nitrous acid treatment of decasaccharide essentially gives one tetrasulfated single-acetylated anhydromannitol tetrasaccharide species (one tagged m/z 5241.5 and one untagged m/z 5186.5). This confirmed that +1-4 (I/GH NA C.6S) is one unit away from the reducing end.
  • Example 5 Sequencing of a Hexasaccharidel of HLGAG.
  • nitrous acid treatment of HI yielded starting material at m/z 5882.5 (1655.8) which corresponded to a hexasaccharide with 8 sulfates and an anhydromannitol at the reducing end, a m/z 5304.1 (1077.3), which corresponded to a tetrasaccharide with the anhydromannitol at the reducing end and a m z of 4726.2 (499.4) which corresponded to a disulfated disaccharide with the anhydromanitol at the reducing end.
  • This sample was then subjected to exoenzyme analysis.
  • Three exoenzymes were added — iduronate 2-0 sulfatase, iduronidase, and glucosamine 6-0 sulfatase.
  • the nitrous acid sample was neutralized via addition of 1/5 volume of 200 mM sodium acetate 1 mg/mL BSA pH 6.0 after which the enzymes were added.
  • Glucosamine 6-0 sulfatase was added after digestion with the first two enzymes was complete. Final enzyme concentrations were in the range of 20-40 milliunits/mL and digestion was carried out at 37°C for a minimum of two hours.
  • Example 6 Sequencing of other complex polysaccharides
  • the sequencing approach may be readily extended to other complex polysaccharides by developing appropriate experimental constraints.
  • DCMP dermatan/chondroitin mucopolysaccharides
  • the minimum difference between any disaccharide and any tetrasaccharide is 139.2 Da, therefore, the length, the number of sulfates and acetates may be readily assigned for a given DCM polysaccharide up to an octa-decasaccharide.
  • PSA polysialic acids
  • NAN 5-N-acetylneuraminic acid
  • NNN 5-N-glycolylneuraminic acid
  • the hexadecimal coding system may be easily extended to NAN/NGN to encode the variations in the functional groups and enabling a sequencing approach for PSA. 1.
  • DCMP Dermatan/ chondroitin family of complex mucopolysaccharides
  • the basic repeat unit of the dermatan chondroitin mucopolysaccharides (DCMP) may be represented as - ( ⁇ 1 ->4) U2 ⁇ -( / ⁇ 1 ->3) GalNAc.4x. ex; where U is uronic acid, Gal NAc is a N-acetylated galactosamine.
  • the uronic acid may be glucuronic acid (G) or iduronic acid (I) and sulfated at the 2-0 position and the galactosamine (GalNAc) may be sulfated in the 4-0 or the 6-0 position, thereby resulting in 16 possible combinations or building blocks for DCMP.
  • G glucuronic acid
  • I iduronic acid
  • GalNAc galactosamine
  • chondoroitinases and other chemical methods available that clip at specific glycosidic linkages of DCMP and serve as experimental constraints.
  • DCMPs are acidic polysaccharides, the MALDI-MS techniques and methods used for HLGAGs may be readily extended to the DCMPs.
  • PEN scheme and mass-identity relationships for DCMP Shown in Table 10 are the property-encoded nomenclature (PEN) of the 16 possible building blocks of dermatan/chondroitin family of molecules.
  • PEN property-encoded nomenclature
  • the sequencing approach enables one to establish important mass-identity relationships as well as master list of all possible DCMP sequences from disaccharides to dodecasaccharides. These are plotted as a mass line as shown in Figure 8.
  • HLGAGs there is a unique signature associated with length and composition for a given mass. As described above the minimum difference between any disaccharide and any tetrasaccharide was found to be 101 Daltons for HLGAGs.
  • Table 10 shows the Property Encoding Numerical scheme used to code DCMPs.
  • the first column codes for the isomeric state of the uronic acid (0 corresponding to iduronic and 1 corresponding to glucuronic).
  • the second column codes for the substitution at the 2-0 position of the uronic acid (0-unsulfatedJ -sulfated) .
  • Columns 3 and 4 code for the substitution at the 4 and 6 position of the galactosamine.
  • Column 5 shows the numeric code for the disaccharide unit
  • column 6 shows the disaccharide unit
  • column 7 shows the theoretical mass calculated for the disaccharide unit.
  • HLGAGs there are chondroitinases that degrade chondroitin-like and dermatan-like regions of DCMP.
  • the chondroitinases B, C, AC and ABC have distinct specificities with some overlap. For the most part the chondroitinases cover the entire range of linkages found in DCMP.
  • Serpin HCF-2 binding DCMP hexasaccharide A. Serpin HCF-2 binding DCMP hexasaccharide
  • the minimum size DCMP binding to serpin HCF-2 was isolated and its composition was determined using elaborate methods which included anion exchange chromatography, paper electrophoresis and paper chromatography.
  • the sequencing strategy through the integration of PEN and MS established the identity of this serpin HCF-2 binding saccharide to be a hexasaccharide with 6 sulfates and 3 acetates.
  • the high degree of sulfation pointed to a dermatan-like saccharide. Since this saccharide was derived using partial N-deacetylation and nitrous acid treatment, it comprises a 5 membered anhydrotalitol ring at the reducing end. Composition analysis of the saccharide may be obtained by degradation using the chondroitinases.
  • composition shows the presence of ⁇ U 2S Gal NA c, 4 s ( ⁇ 5) and ⁇ U 2 saTal 4S (aTal - anhydrotalitol - ⁇ 5') in a 2:1 ratio.
  • 2-sulfatase and iduronidase treatment of the hexasaccharide produced a shift in the mass spectrum corresponding to the loss of a sulfate and iduronate, thereby fixing the I 2 s at non-reducing end (Table 1 lb).
  • Polysialic acids are linear complex polysaccharides found as a highly regulated post-translational modification of the neural cell adhesion molecule in mammals that are present mostly as homopolymers of 5-N-acetylneuraminic acid (NAN) or 5-N- glycoiylneuraminic acid (NGN).
  • NAN 5-N-acetylneuraminic acid
  • NGN 5-N- glycoiylneuraminic acid
  • the monomeric units of NAN and NGN are linked by ⁇ 2-8 glycosidic linkages, and may be modified at the 4-O, 7-O, and 9-0 positions.
  • the major modification is acetylation.
  • PSA is comprised of two different monomeric repeats, with variations in the modification of each unit.
  • the flexibility of the PEN enables easy adaptation to a monomeric repeat unit for PSA from the dimeric repeats for HLGAG and DCMP.
  • the PEN scheme for PSA is shown in Table 13.
  • the sequencing approach establishes important mass-identity relationships as well as master list of all the combinations of monomeric units for NAN and NGN.
  • the mass-line for polymeric units of NAN and NGN are shown in Fig. 9 A and 9B. Note that there is a considerable overlap in masses observed for the higher order ohgomers of both NAN and NGN ( Figure 9A and 9B).
  • the minimum difference in the masses between a n 'mer and a n+1 'mer stabilizes at 3.01Da for NAN and 13Da for NGN, as we go to tetra, penta and hexasaccharide, thereby providing a safe margin for detection of these fragments using MS.
  • Table 13 Shown in Table 13 is the Property Encoded Numerical scheme for PSA.
  • Column 1 codes for whether the monomeric unit is NAN or NGN.
  • Columns 2,3 and 4 code for the variations in the 9, 7 and 4 positions respectively, where 1 corresponds to acetylated and 0 corresponds to unacetylated.
  • Column 5 shows the numeric code for the PSAs. -0 to -7 was used instead of 8-F. Assigning the numbers to code for the variability in acetylation and the sign would indicate if it is NAN/NGN.
  • Column 6 lists the monosaccharide represented by the code in column 5.
  • Column 7 lists the theoretical mass calculated for the monomeric units shown in column 6.
  • the mass-line for the combinations of substituted/unsubstituted NAN containing monomeric units in PSA is shown in Figure 9A.
  • the X-axis represents the calculated masses for monosaccharide to hexasaccharides. Shown in the Y axis is the number of fragments of a particular length and composition that exists for a given mass. The values 150-190 were omitted to improve the clarity of the other peaks.
  • the minimum difference between any monosaccharide and any disaccharide is 165.2Da, between any di and any trisaccharide is 39.03Da, between any tri and any tetrasaccharide is 39.03Da and 3.01 Da for all higher order saccharides.
  • the mass-line for the combinations of substituted/unsubstituted NGN monomeric units in PSA is shown in Figure 9B.
  • the X-axis represents the calculated masses for monosaccharaide to hexasaccharide. Shown in the Y axis is the number of fragments of a particular length and composition that exist for a given mass. The values 150-190 were omitted to improve the clarity of the other peaks.
  • the minimum difference between any monosaccharide and any disaccharide is 181.2Da, between any di and any trisaccharide is 55.03Da and 13Da for higher order saccharides.
  • Example 7 Variation of experimental conditions resulting in alteration of enzymatic reactions and its effect on the methods of the invention.
  • Figure 10A shows cleavage by recombinant heparinase III of tetrasaccharides containing either G (•), I(o) or I 2 s ( ⁇ ) linkages. Each reaction was followed by capillary electrophoresis. With these substrates, heparinase III does not cleave ⁇ -containing glycosidic linkages, and cleaves G-containing linkages roughly 10 times as fast as I-containing linkages. Under the "short" conditions of digest it is expected that only G-containing saccharides are cleaved to an appreciable extent.
  • reaction was allowed to proceed at room temperature with quenching of aliquots at various time points via the addition of 1 ⁇ L of 200 mM sodium acetate 1 mg/mL BSA pH 6.0.
  • Exhaustive nitrous acid was completed by reacting saccharide with 4 mM nitrous acid in HC1 overnight at room temperature. In both cases, it was found that the products of nitrous acid cleavage could be sampled directly by MALDI without further cleanup and without the need to reduce the anhydromannose residues to anhydromannitol.
  • HLGAG degrading exoenzymes were purchased from Oxford Glycosystems (Wakefield, MA) and used as suggested by the manufacturer.] For example, with the hexasaccharide ⁇ UHNH,6SGHNSIHNA O (which contains both I and G in a minimally sulfated region) cleavage occurs only at the G under "short" digest conditions as shown in Table 14.
  • Heparinase II was incubated with the hexasaccharide AUHN H .
  • OS GHN S IH NHC and only cleavage at the G and not the I was observed.
  • degree of sulfation does affect the kinetics of heparinase III degradation of oligosaccharides [S. Ernst et al., Crit. Rev. Biochem. Mol. Biol. 30, 387 (1995); S. Yamada et al., Glycobiology 4, 69 (1994); U.R. Desai, H.M. Wang, RJ. Linhardt,
  • the second problem is the preparation of pure wild-type heparinases from the native host.
  • the wild-type heparinase is isolated from Flavobacterium heparinum and this organism produces several complex polysaccharide- degrading enzymes, and often these copurify with each other.
  • heparinase III when examining the kinetics of heparinase III. we found that a commercial source of heparinase III was able to degrade the supposedly non-cleavable ⁇ U2 S H NS , 6S I 2S H NS , 6S - Furthermore, MS and CE analysis of the products indicated that one was specifically 2-0 desulfated suggesting a sulfatase contamination.
  • Recombinant heparinase III produced and purified in our laboratory does not cleave ⁇ U2 S HN S , 6S I2 S H N S,6S as expected.
  • different enzyme preparations and differences in digestion conditions, and differences in substrate size and composition and often contaminating substrates, taken together with assignments based on co-elution make comparison of data not only very difficult but also has led to contradictory findings.
  • heparinase substrate specificities there are other methods that may be used to extract the isomeric state of the uronic acid [I or G or I 2 s or G 2 s]-
  • the uronic acid component of each disaccharide unit may be unambiguously ascertained by completing compositional analysis after exhaustive nitrous acid treatment.
  • compositional analysis of given oligosaccharides may be accomplished and the presence of G2 S , I2S, I and G containing building blocks assessed. With this information, rapid convergence to a single sequence could be completed by judicious application of the heparinases (regardless of their exact substrate specificity), since cleavage would give mass information on either side of the cleavage site.
  • Example 8 Methods for identifying protein-polysaccharide interactions and improved methods for sequencing.
  • HLGAG sequences that bind to a particular protein the most common methodology involves affinity fractionation of oligosaccharides using a particular HLGAG subset, namely porcine intestinal mucosa heparin.
  • Enzymatically or chemically derived heparin oligosaccharides of a particular length are passed over a column of immobilized protein. After washing, the bound fraction is eluted using high salt to disrupt interactions between the sulfates on the polysaccharide and basic residues on the protein; interactions which are crucial for binding.
  • Eluted oligosaccharides are then characterized, typically by NMR. In this manner, sequences that bind to a number of proteins, including antithrombin III (AT-III), basic fibroblast growth factor (FGF-2), and endostatin have been identified.
  • AT-III antithrombin III
  • FGF-2 basic fibroblast growth factor
  • HLGAG-binding proteins sample and bind to the more structurally diverse heparan sulfate (HS) chains of proteoglycans at the cell surface where heparin- like sequences (i.e., sequences with a high degree of sulfation) do not always predominate.
  • HS heparan sulfate
  • FGF-2 binds to a specific subset of heparan sulfate sequences that contain a critical 2-O sulfated iduronate residue.
  • rigorous examination of the crystal structures of FGF-2, including co-crystals of FGF with HLGAG oligosaccharides indicates that only three contacts between sulfates and basic residues on FGF-2 are important for high affinity binding.
  • ATIII Protein preparation and immobilization. ATIII was incubated overnight with excess porcine mucosal heparin, then biotinylated with EZ-link sulfo-NHS biotin (Pierce). Canon NP Type E transparency film was taped to the MALDI sample plate and used as a protein immobilization surface. FGF-1 and FGF-2 were immobilized by spotting 1 ⁇ l of aqueous solution on the film and air-drying. ATIII was immobilized by first drying 4 ⁇ g neutravidin on the film surface, then adding biotinylated ATIII to the neutravidin spot. Heparin was removed by washing ten times with IM NaCl and ten times with water. Saccharide binding, selection and analysis.
  • Saccharides were derived from a partial digest of porcine mucosal heparin by heparinase I. The hexasaccharide fraction was obtained by size exclusion chromatography on Biogel P-6 and lyophilized to dryness. Saccharides were bound to immobilized proteins by spotting 1 ⁇ l of aqueous solution on the protein spot for at least five minutes. Unbound saccharides were removed by washing with water fifteen times. For selection experiments, the spot was washed ten times with various NaCl concentrations, followed by ten water washes. Caffeic acid matrix in 50% acetonitrile with 2pmol/ ⁇ l (RG) 19 R was added to the spot prior to MALDI analysis. All saccharides were detected as noncovalent complexes with (RG) ]9 R using MALDI parameters described herein.
  • Saccharide digestion by heparinase I or III Saccharides selected for FGF-2 binding were digested with heparinases I or III by spotting 8 ⁇ g of enzyme in water after selection was completed. The spot was kept wet for the desired digestion time by adding water as necessary. Caffeic acid matrix with 2pmol/ ⁇ l (RG) 19 R was added to the spot for MALDI analysis.
  • Bovine aortic smooth muscle cells (SMCS) were grown to confluency. Cells were washed twice with PBS and then 200 nM heparinase III was added for 1 hr. The supernatant was heated to 50°C for 10 minutes to inactivate heparinase III and filtered. To remove polynucleotide contamination, the samples were treated with DNAse and RNAse at room temperature overnight. Heparan sulfate was isolated by binding to a DEAE filter, washing away unbound material, and elution using 10 mM sodium phosphate IM NaCl pH 6.0.
  • FGF-1 which has been shown to have similar binding properties as FGF-2, could also select for the octa- and nonasulfated hexasaccharides from a mixture.
  • Sequencing saccharides on the MALDI surface The highly sensitive sequencing methodology of the invention was used to test whether we could derive structural information of FGF high affinity binders on target.
  • the octa- and nonasulfated saccharides were subjected to enzymatic and chemical depolymerization. After saccharide selection, the saccharide sample was depolymerized by heparinase I to obtain sequence information.
  • the nonasulfated hexasaccharide was reduced to a single trisulfated disaccharide indicating that this saccharide is a repeat of [I 2S H NS , 6S ]- Digestion of the octasulfated hexasaccharide yielded the trisulfated disaccharide and a pentasulfated tetrasaccharide. That this tetrasaccharide contains an unsulfated uronic acid was confirmed by heparinase III cleavage, which resulted in the disappearance of the tetrasaccharide.
  • sequence of the nonasulfated hexasaccharide is ⁇ DDD ( ⁇ U 2S H NS,OS I 2S H NS , 6 SI2 S HN S , 6S ) and the sequence of the octasulfated hexasaccharide is ⁇ DD-5.
  • ATIII is heavily glycosylated, therefore we anticipated that it would not bind well to the MALDI plate.
  • avidin was immobilized on the plate and biotinylated AT-III was bound to the avidin.
  • the ATIII biotinylation reaction was carried out in the presence of heparin to protect the protein's binding site for HLGAG oligosaccharides.
  • penta 1, that contains an intact AT-III pentasaccharide binding sequence was used to verify that the protein was immobilized on the surface and was able to bind saccharides. Penta 1 binding to ATIII was observed up to washes of 0.5M NaCl, consistent with it being a strong binder to ATIII.
  • FGF-2 Binders in SMC HS. Heparan sulfate at the cell surface of SMCs is known to contain high affinity sites for FGF binding. In an effort to extend our initial studies with highly sulfated heparin, we sought to identify high affinity FGF binders in heparan sulfate proteoglycans at the cell surface of SMCs. To this end, SMCs were treated with either heparinase I or heparinase III and the HLGAGs isolated and purified. Consistent with the known substrate specificity of the enzymes, the composition of released fragments is different. Fragments were then treated with heparinase II to reduce them in size.
  • the digest was spotted on FGF-2 and selection process was accomplished as outlined above. Consistent with our findings with heparin, a single hexasaccharide was identified to be a high affinity binder for FGF-2, namely the nonasulfated hexasaccharide with a sequence +DDD.
  • the above-methodology describes an alternative protocol for the selection of saccharide binders to proteins.
  • This methodology has been applied towards the identification of oligosaccharides derived from heparin that bind to two well-established systems, FGF and ATIII. As shown, this procedure produces identical results to the more established methodology of affinity fractionation.
  • FGF-1 and FGF-2 high affinity binders can be selected out of a pool of similar saccharides.
  • ATIII can be selected for high affinity binders over binders that contain only a partial binding site.
  • This methodology has a number of critical advantages over prior art strategies.
  • Such an advance makes it feasible to use the more biologically relevant HS isolated from the cell surface as substrates, rather than highly sulfated heparin from mast cells.
  • the Example demonstrated this technique for the chemically complex and information dense HLGAGs, it is widely applicable towards identifying other polysaccharide-protein interactions.
  • Example 9 Methods for identifying branching and methods for sequencing branched polysaccharides.
  • glycosylation patterns are highly influenced by the phenotype of the cell.
  • glycan structure especially in the degree of branching.
  • GlcNAc residues in pathogenic versus normal prion proteins, there is a decrease in levels of glycans with bisecting GlcNAc residues and increased levels of tri- and tetrantennary structures.
  • judicious application of enzymatic and chemical degradation the identity of branched chains may also be identified.
  • FIG. 12 is data arising from MALDI-MS microsequencing of the PSA polysaccharide structure.
  • MALDI-MS was completed using 500 fmol of saccharide. Analysis was completed with a saturated aqueous solution of 2,5-dihydroxybenzoic with 300 mM spermine as an additive. Analytes were detected in the negative mode at an accelerating voltage of 22 kV. 1 ⁇ L of matrix was added to 0.5 ⁇ L of aqueous sample and allowed to dry on the target.
  • A MS of the intact polysaccharide structure.
  • FIG. 13 shows the results of sequencing the sugar of PSA (Sigma Chemical).
  • Figure 13 shows the results of enzymatic degradation of the saccharide chain directly off of PSA. 50 pmol of PSA (-1.4 ⁇ g) of PSA was denatured by heat treatment at 80°C for 20 minutes. Then the sample was sequentially treated with the exoenzymes (B-D). After overnight incubation at 37°C, 1 pmol of the digested PSA was examined by mass spectrometry.
  • aqueous sample was mixed with sinapinic acid in 30% acetonitrile, allowed to dry, and then examined by MALDI TOF. All spectra were calibrated externally with a mixture of myoglobin, ovalbumin, and BSA to ensure accurate molecular mass determination.
  • A PSA before the addition of exoenzymes. The measured mass of 28,478 agreed well with the reported value of 28,470.
  • B Treatment of (A) with sialidase resulted in a mass decrease of 287 Da, consistent with the loss of one sialic acid residue.
  • C Treatment of (B) with galactosidase. A further decrease of 321 Da indicated the loss of two galactose moieties.
  • D Upon digestion of (C) with hexosaminidase, a decrease of 393 Da indicated the loss of two N-acetylglucosamine residues.
  • the protein had a measured mass of 28,478.3 (Figure 13A).
  • Treatment of the intact protein with sialidase resulted in a decrease of 287 Da, consistent with the loss of one sialic acid residue ( Figure 13B).
  • Additional treatment with galactosidase resulted in a decrease in mass of 321, consistent with the loss of two galactose residues ( Figure 13C).
  • Treatment with N acetylhexosaminidase resulted in cleavage of two GlcNAc moieties ( Figure 13D).
  • EndoF2 is an endoglycanase that clips only biantennary structures. Tri- and tetrantennary structures do not serve as substrates for this enzyme ( Figure 14) .
  • EndoF2 treatment of a glycan structure either attached to the protein or after isolation, was used to identify branching identity. This becomes especially important in light of the fact that aberrant changes in glycosylation patterns usually result in increased branching.
  • EndoF2 was used to cleave glycan structures that were still attached to the protein of interest.
PCT/US2000/010990 1999-04-23 2000-04-24 System and method for polymer notation WO2000065521A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00923599A EP1190364A2 (en) 1999-04-23 2000-04-24 System and method for polymer notation
JP2000614193A JP4824170B2 (ja) 1999-04-23 2000-04-24 ポリマーを表記するためのシステムおよび方法
CA002370539A CA2370539C (en) 1999-04-23 2000-04-24 System and method for notating polymers

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US13079299P 1999-04-23 1999-04-23
US13074799P 1999-04-23 1999-04-23
US15994099P 1999-10-14 1999-10-14
US15993999P 1999-10-14 1999-10-14
US60/159,939 1999-10-14
US60/130,747 1999-10-14
US60/159,940 1999-10-14
US60/130,792 1999-10-14

Publications (2)

Publication Number Publication Date
WO2000065521A2 true WO2000065521A2 (en) 2000-11-02
WO2000065521A3 WO2000065521A3 (en) 2001-10-25

Family

ID=27494876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/010990 WO2000065521A2 (en) 1999-04-23 2000-04-24 System and method for polymer notation

Country Status (5)

Country Link
US (8) US6597996B1 (US20030191587A1-20031009-C00001.png)
EP (1) EP1190364A2 (US20030191587A1-20031009-C00001.png)
JP (1) JP4824170B2 (US20030191587A1-20031009-C00001.png)
CA (2) CA2370539C (US20030191587A1-20031009-C00001.png)
WO (1) WO2000065521A2 (US20030191587A1-20031009-C00001.png)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
EP1590648A2 (en) * 2002-05-20 2005-11-02 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
WO2008153504A1 (en) * 2007-06-15 2008-12-18 Agency For Science, Technology And Research System and method for representing n-linked glycan structures
US7507570B2 (en) 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
US7695711B2 (en) 2002-05-03 2010-04-13 Massachusetts Institute Of Technology Δ 4,5 glycuronidase nucleic acid compositions
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
EP2284535A1 (en) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
US8000904B2 (en) 2004-04-15 2011-08-16 Momenta Pharmaceuticals, Inc. Methods and products related to the improved analysis of carbohydrates
EP2441830A2 (en) 2005-11-03 2012-04-18 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US8209132B2 (en) 2004-04-15 2012-06-26 Momenta Pharmaceuticals, Inc. Methods and products related to the improved analysis of carbohydrates
US8435795B2 (en) 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
WO2000065521A2 (en) * 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
US7226739B2 (en) * 2001-03-02 2007-06-05 Isis Pharmaceuticals, Inc Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
EP1438387A4 (en) * 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
US20040214228A9 (en) * 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
EP1345167A1 (en) * 2002-03-12 2003-09-17 BRITISH TELECOMMUNICATIONS public limited company Method of combinatorial multimodal optimisation
EP1532241B1 (en) * 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
WO2004066808A2 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
WO2005026720A1 (en) * 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
US20050178959A1 (en) * 2004-02-18 2005-08-18 Viorica Lopez-Avila Methods and compositions for assessing a sample by maldi mass spectrometry
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
US20060264713A1 (en) * 2005-05-20 2006-11-23 Christoph Pedain Disease and therapy dissemination representation
GB0514553D0 (en) * 2005-07-15 2005-08-24 Nonlinear Dynamics Ltd A method of analysing a representation of a separation pattern
GB0514552D0 (en) * 2005-07-15 2005-08-24 Nonlinear Dynamics Ltd A method of analysing representations of separation patterns
BRPI0614850A2 (pt) * 2005-08-19 2011-04-19 Centocor Inc preparações de anticorpos resistentes a proteólise
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease
WO2008060570A1 (en) * 2006-11-14 2008-05-22 Abb Inc. System for storing and presenting sensor and spectral data for batch processes
US7301339B1 (en) * 2006-12-26 2007-11-27 Schlumberger Technology Corporation Estimating the concentration of a substance in a sample using NMR
US8069127B2 (en) * 2007-04-26 2011-11-29 21 Ct, Inc. Method and system for solving an optimization problem with dynamic constraints
US8093056B2 (en) * 2007-06-29 2012-01-10 Schlumberger Technology Corporation Method and apparatus for analyzing a hydrocarbon mixture using nuclear magnetic resonance measurements
US20100049445A1 (en) * 2008-06-20 2010-02-25 Eureka Genomics Corporation Method and apparatus for sequencing data samples
EP4032538A3 (en) 2009-03-02 2022-10-26 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
US8063374B2 (en) * 2009-09-22 2011-11-22 California Polytechnic Corporation Systems and methods for determining recycled thermoplastic content
BR112012025645A2 (pt) 2010-04-07 2017-12-12 Momenta Pharmaceuticals Inc glicanos de alta manose.
US20140166875A1 (en) 2010-09-02 2014-06-19 Wayne State University Systems and methods for high throughput solvent assisted ionization inlet for mass spectrometry
US8853621B2 (en) 2010-10-25 2014-10-07 Wayne State University Systems and methods extending the laserspray ionization mass spectrometry concept from atmospheric pressure to vacuum
CN103782168B (zh) 2011-03-12 2016-03-16 动量制药公司 在糖蛋白产品中包含n-乙酰己糖胺的n-聚醣
EP3950704A1 (en) 2011-03-15 2022-02-09 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
WO2013177385A1 (en) * 2012-05-23 2013-11-28 The Johns Hopkins University Mass spectrometry imaging of glycans from tissue sections and improved analyte detection methods
WO2013181575A2 (en) 2012-06-01 2013-12-05 Momenta Pharmaceuticals, Inc. Methods related to denosumab
EP2855533A4 (en) 2013-03-15 2015-11-25 Momenta Pharmaceuticals Inc METHODS RELATING TO CTLA4-FC FUSION PROTEINS
US10464996B2 (en) 2013-05-13 2019-11-05 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
JP6847660B2 (ja) 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN104572622B (zh) * 2015-01-05 2018-01-02 武汉传神信息技术有限公司 一种术语的筛选方法
US10381108B2 (en) * 2015-09-16 2019-08-13 Charles Jianping Zhou Web search and information aggregation by way of molecular network
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
EP3452407B1 (en) 2016-05-05 2024-04-03 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
KR102115390B1 (ko) * 2016-07-26 2020-05-27 주식회사 엘지화학 중합체 변성률 측정 방법
US11519905B2 (en) 2017-04-07 2022-12-06 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
DE102018000650A1 (de) * 2018-01-27 2019-08-01 Friedrich-Schiller-Universität Jena Verfahren zur Bestimmung von Verunreinigungen in Polyalkylenethern oder Polyalkylenaminen und dessen Verwendung
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
US20230222313A1 (en) * 2022-01-12 2023-07-13 Dell Products L.P. Polysaccharide archival storage

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5687090A (en) * 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
US5752019A (en) * 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification

Family Cites Families (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE449753B (sv) 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
US4692435A (en) 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
CA1136620A (en) 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4281108A (en) 1980-01-28 1981-07-28 Hepar Industries, Inc. Process for obtaining low molecular weight heparins endowed with elevated pharmacological properties, and product so obtained
US4443545A (en) 1980-08-25 1984-04-17 Massachusetts Institute Of Technology Process for producing heparinase
US4341869A (en) 1980-08-25 1982-07-27 Massachusetts Institute Of Technology Process for producing heparinase
US4373023A (en) 1980-10-14 1983-02-08 Massachusetts Institute Of Technology Process for neutralizing heparin
US4396762A (en) 1981-08-24 1983-08-02 Massachusetts Institute Of Technology Heparinase derived anticoagulants
NL8200334A (nl) 1982-01-29 1983-08-16 Otsuka Pharma Co Ltd Werkwijze voor het bepalen van met tumoren geassocieerde glucosidische bindingen en werkwijze voor de diagnose van kanker.
US4551296A (en) * 1982-03-19 1985-11-05 Allied Corporation Producing high tenacity, high modulus crystalline article such as fiber or film
US4757056A (en) 1984-03-05 1988-07-12 Hepar Industries, Inc. Method for tumor regression in rats, mice and hamsters using hexuronyl hexosaminoglycan-containing compositions
US4679555A (en) 1984-08-07 1987-07-14 Key Pharmaceuticals, Inc. Method and apparatus for intrapulmonary delivery of heparin
US5106734A (en) 1986-04-30 1992-04-21 Novo Nordisk A/S Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin
DE3787996T2 (de) 1986-05-16 1994-03-03 Italfarmaco Spa Heparine, frei von E.D.T.A., Fraktionen und Fragmente von Heparin, Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, welche diese enthalten.
US4784820A (en) 1986-08-11 1988-11-15 Allied-Signal Inc. Preparation of solution of high molecular weight polymers
US4745105A (en) 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4942156A (en) 1986-08-20 1990-07-17 Hepar Industries, Inc. Low molecular weight heparin derivatives having improved anti-Xa specificity
US4830013A (en) 1987-01-30 1989-05-16 Minnesota Mining And Manufacturing Co. Intravascular blood parameter measurement system
FR2614026B1 (fr) 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
SE8702254D0 (sv) 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
US5169772A (en) 1988-06-06 1992-12-08 Massachusetts Institute Of Technology Large scale method for purification of high purity heparinase from flavobacterium heparinum
IT1234508B (it) 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826448D0 (en) 1988-11-11 1988-12-14 Thrombosis Res Inst Improvements in/relating to organic compounds
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
CA1340966C (en) * 1989-05-19 2000-04-18 Thomas R. Covey Method of protein analysis
IT1237518B (it) 1989-11-24 1993-06-08 Renato Conti Eparine supersolfatate
GB8927546D0 (en) 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
US5152784A (en) 1989-12-14 1992-10-06 Regents Of The University Of Minnesota Prosthetic devices coated with a polypeptide with type IV collagen activity
FR2663639B1 (fr) 1990-06-26 1994-03-18 Rhone Poulenc Sante Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
US5284558A (en) 1990-07-27 1994-02-08 University Of Iowa Research Foundation Electrophoresis-based sequencing of oligosaccharides
IT1245761B (it) 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
JP3110064B2 (ja) 1991-03-06 2000-11-20 生化学工業株式会社 新規ヘパリチナーゼ、その製造法及びその生産菌
US5262325A (en) 1991-04-04 1993-11-16 Ibex Technologies, Inc. Method for the enzymatic neutralization of heparin
CZ232593A3 (en) 1991-05-02 1994-07-13 Yeda Res & Dev Pharmaceutical preparation for preventing and/or therapy of pathological states
EG20399A (en) 1991-06-13 1999-02-28 Dow Chemical Co A soft segment isocyanate terminate prepolymer and polyurethane elastomer therefrom
US5714376A (en) 1991-10-23 1998-02-03 Massachusetts Institute Of Technology Heparinase gene from flavobacterium heparinum
IT1254216B (it) 1992-02-25 1995-09-14 Opocrin Spa Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono
US5453171A (en) 1992-03-10 1995-09-26 The Board Of Regents Of The University Of Michigan Heparin-selective polymeric membrane electrode
US5856928A (en) 1992-03-13 1999-01-05 Yan; Johnson F. Gene and protein representation, characterization and interpretation process
GB9206291D0 (en) 1992-03-23 1992-05-06 Cancer Res Campaign Tech Oligosaccharides having growth factor binding affinity
US5389539A (en) 1992-11-30 1995-02-14 Massachusetts Institute Of Technology Purification of heparinase I, II, and III from Flavobacterium heparinum
US5696100A (en) 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
GB9306255D0 (en) 1993-03-25 1993-05-19 Cancer Res Campaign Tech Heparan sulphate oligosaccharides having hepatocyte growth factor binding affinity
FR2704861B1 (fr) 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
JPH09508892A (ja) 1993-11-17 1997-09-09 マサチューセッツ インスティテュート オブ テクノロジー ヘパリナーゼを用いる血管形成の阻害方法
US6013628A (en) 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
US5607859A (en) 1994-03-28 1997-03-04 Massachusetts Institute Of Technology Methods and products for mass spectrometric molecular weight determination of polyionic analytes employing polyionic reagents
US5658749A (en) 1994-04-05 1997-08-19 Corning Clinical Laboratories, Inc. Method for processing mycobacteria
US5753445A (en) 1994-04-26 1998-05-19 The Mount Sinai Medical Center Of The City University Of New York Test for the detection of anti-heparin antibodies
JPH09512822A (ja) 1994-05-06 1997-12-22 グリコメド・インコーポレイテッド O−脱硫酸化ヘパリン誘導体とその製造法および使用
US5681733A (en) 1994-06-10 1997-10-28 Ibex Technologies Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
US5619421A (en) 1994-06-17 1997-04-08 Massachusetts Institute Of Technology Computer-implemented process and computer system for estimating the three-dimensional shape of a ring-shaped molecule and of a portion of a molecule containing a ring-shaped structure
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
FR2723847A1 (fr) 1994-08-29 1996-03-01 Debiopharm Sa Compositions antithrombotiques et non hemorragiques a base d'heparine, procede pour leur preparation et applications therapeutiques.
AU700903B2 (en) 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
JP2927401B2 (ja) * 1994-12-28 1999-07-28 日本ビクター株式会社 ヘリキャルスキャン型情報記録装置
US5569366A (en) 1995-01-27 1996-10-29 Beckman Instruments, Inc. Fluorescent labelled carbohydrates and their analysis
US5618917A (en) 1995-02-15 1997-04-08 Arch Development Corporation Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US5763427A (en) 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5597811A (en) 1995-04-10 1997-01-28 Amerchol Corporation Oxirane carboxylic acid derivatives of polyglucosamines
JP3318578B2 (ja) 1995-05-26 2002-08-26 サーモディックス,インコーポレイティド 内皮化を促進するための方法及び移植用製品
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
US5770420A (en) * 1995-09-08 1998-06-23 The Regents Of The University Of Michigan Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures
CA2235223A1 (en) 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
CZ343798A3 (cs) 1996-04-29 1999-02-17 Dura Pharmaceuticals, Inc. Inhalační systém pro inhalaci suchého prášku
US6228654B1 (en) 1996-05-09 2001-05-08 The Scripps Research Institute Methods for structure analysis of oligosaccharides
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU727352B2 (en) 1996-07-29 2000-12-14 Paringenix, Inc. Methods of treating asthma with o-desulfated heparin
US6642363B1 (en) 1996-09-19 2003-11-04 The Regents Of The University Of Michigan Polymers containing polysaccharides such as alginates or modified alginates
US5767269A (en) 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US5803726A (en) * 1996-10-04 1998-09-08 Bacon; David W. Retractable, electric arc-ignited gas pilot for igniting flare stacks
US5759767A (en) 1996-10-11 1998-06-02 Joseph R. Lakowicz Two-photon and multi-photon measurement of analytes in animal and human tissues and fluids
US6642360B2 (en) * 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
GB9708278D0 (en) 1997-04-24 1997-06-18 Danisco Composition
US5968822A (en) 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US6190875B1 (en) 1997-09-02 2001-02-20 Insight Strategy & Marketing Ltd. Method of screening for potential anti-metastatic and anti-inflammatory agents using mammalian heparanase as a probe
US6268146B1 (en) * 1998-03-13 2001-07-31 Promega Corporation Analytical methods and materials for nucleic acid detection
US6190522B1 (en) 1998-04-24 2001-02-20 Board Of Regents, The University Of Texas System Analysis of carbohydrates derivatized with visible dye by high-resolution polyacrylamide gel electrophoresis
AU4707899A (en) * 1998-06-23 2000-01-10 Pioneer Hi-Bred International, Inc. Alteration of hemicellulose concentration in plants by rgp
US5985576A (en) * 1998-06-30 1999-11-16 The United States Of America As Represented By The Secretary Of Agriculture Species-specific genetic identification of Mycobacterium paratuberculosis
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (en) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
US6653076B1 (en) 1998-08-31 2003-11-25 The Regents Of The University Of Washington Stable isotope metabolic labeling for analysis of biopolymers
US6291439B1 (en) 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
US6440705B1 (en) 1998-10-01 2002-08-27 Vincent P. Stanton, Jr. Method for analyzing polynucleotides
US6610484B1 (en) 1999-01-26 2003-08-26 Cytyc Health Corporation Identifying material from a breast duct
US6429302B1 (en) 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
WO2000065521A2 (en) 1999-04-23 2000-11-02 Massachusetts Institute Of Technology System and method for polymer notation
JP3689842B2 (ja) 1999-05-28 2005-08-31 株式会社J−オイルミルズ 糖組成物の単糖分析方法
PT1172466E (pt) 2000-02-16 2007-04-30 Teijin Ltd Processo para a produção de uma fibra de poliamida inteiramente aromática de tipo meta.
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
JP4911865B2 (ja) 2000-09-12 2012-04-04 マサチューセッツ インスティテュート オブ テクノロジー 低分子量ヘパリンに関連する方法および生成物
CA2423469A1 (en) * 2000-10-18 2002-04-25 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
EP2479578A1 (en) 2000-10-19 2012-07-25 Target Discovery, Inc. Mass defect labeling for the determination of oligomer sequences
AU2002306921A1 (en) * 2001-03-27 2002-10-08 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
US20030008326A1 (en) 2001-05-30 2003-01-09 Sem Daniel S Nuclear magnetic resonance-docking of compounds
US6766817B2 (en) * 2001-07-25 2004-07-27 Tubarc Technologies, Llc Fluid conduction utilizing a reversible unsaturated siphon with tubarc porosity action
EP1438387A4 (en) 2001-09-14 2004-10-13 Momenta Pharmaceuticals Inc METHODS OF MAKING GLYCOMOLECULES WITH IMPROVED ACTIVITY, AND USES THEREOF
US20040214228A9 (en) 2001-09-14 2004-10-28 Ganesh Venkataraman Methods of evaluating glycomolecules for enhanced activities
US7363168B2 (en) * 2001-10-02 2008-04-22 Stratagene California Adaptive baseline algorithm for quantitative PCR
EP2284535A1 (en) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
JP2006501815A (ja) 2002-04-25 2006-01-19 モメンタ ファーマシューティカルズ インコーポレイテッド 粘膜送達のための方法および製品
EP1575534B1 (en) * 2002-05-03 2013-04-10 Massachusetts Institute Of Technology D4,5 glycuronidase and uses thereof
WO2004055491A2 (en) * 2002-05-20 2004-07-01 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
EP1532241B1 (en) 2002-06-03 2010-09-15 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
WO2004066808A2 (en) 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー 2−oスルファターゼ組成物および関連の方法
WO2005026720A1 (en) 2003-09-04 2005-03-24 Parivid Llc Methods and apparatus for characterizing polymeric mixtures
US7851223B2 (en) 2004-02-27 2010-12-14 Roar Holding Llc Method to detect emphysema
WO2005087920A2 (en) * 2004-03-10 2005-09-22 Massachusetts Institute Of Technology Recombinant chondroitinase abc i and uses thereof
US20060127950A1 (en) * 2004-04-15 2006-06-15 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
WO2005110438A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
WO2005111627A2 (en) * 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the improved analysis of carbohydrates
CA2614068A1 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
WO2006083328A2 (en) * 2004-09-15 2006-08-10 Massachusetts Institute Of Technology Biologically active surfaces and methods of their use
CA2594013A1 (en) * 2005-01-12 2006-07-20 Massachusetts Institute Of Technology Methods and compositions related to modulating the extracellular stem cell environment
WO2006105313A2 (en) * 2005-03-29 2006-10-05 Massachusetts Institute Of Technology Compositions of and methods of using oversulfated glycosaminoglycans
US20090156477A1 (en) * 2005-03-29 2009-06-18 Massachusetts Institute Of Technology Compositions and Methods for Regulating Inflammatory Responses
JP5068748B2 (ja) * 2005-06-22 2012-11-07 ジェン−プロウブ インコーポレイテッド ポリヌクレオチドを定量するための方法およびアルゴリズム
US20080071148A1 (en) * 2006-04-03 2008-03-20 Massachusetts Institute Of Technology Glycomic patterns for the detection of disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5687090A (en) * 1994-09-01 1997-11-11 Aspen Technology, Inc. Polymer component characterization method and process simulation apparatus
US5752019A (en) * 1995-12-22 1998-05-12 International Business Machines Corporation System and method for confirmationally-flexible molecular identification

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ERNST S ET AL: "Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, [Online] vol. 95, April 1998 (1998-04), pages 4182-4187, XP002151745 USA Retrieved from the Internet: <URL:http://www.pnas.org> [retrieved on 2000-10-26] cited in the application *
HAYES B: "Prototeins" AMERICAN SCIENTIST, [Online] vol. 86, no. 3, May 1998 (1998-05) - June 1998 (1998-06), pages 216-221, XP002151746 USA Retrieved from the Internet: <URL:http://www.sigmaxi.org/amsci/issues/Comsci98/compsci199805.pdf> [retrieved on 2000-10-26] *
RUDD P M ET AL: "Oligosaccharide sequencing technology" NATURE, vol. 388, no. 6638, 10 July 1997 (1997-07-10), pages 205-207, XP000953155 *
See also references of EP1190364A2 *
YINGMING ZHAO ET AL: "Rapid, sensitive structure analysis of oligosaccharides" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, [Online] vol. 94, March 1997 (1997-03), pages 1629-1633, XP002151747 USA Retrieved from the Internet: <URL:http://www.pnas.org> [retrieved on 2000-10-26] *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939292B2 (en) 2000-03-08 2011-05-10 Massachusetts Institute Of Technology Modified heparinase III and methods of sequencing therewith
US6869789B2 (en) 2000-03-08 2005-03-22 Massachusetts Institute Of Technology Heparinase III and uses thereof
US7083937B2 (en) 2000-09-12 2006-08-01 Massachusetts Institute Of Technology Methods and products related to the analysis of polysaccarides
US7709461B2 (en) 2000-10-18 2010-05-04 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
EP2284535A1 (en) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Low molecular weight heparins
US8715953B2 (en) 2002-03-11 2014-05-06 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
EP2402753A1 (en) 2002-03-11 2012-01-04 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7947507B2 (en) 2002-03-11 2011-05-24 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
US7951560B2 (en) 2002-05-03 2011-05-31 Massachusetts Institute Of Technology Delta 4,5 glycuronidase compositions and methods related thereto
US7695711B2 (en) 2002-05-03 2010-04-13 Massachusetts Institute Of Technology Δ 4,5 glycuronidase nucleic acid compositions
EP1590648A4 (en) * 2002-05-20 2007-04-18 Massachusetts Inst Technology NEW TECHNIQUE FOR MRI SEQUENCE DETERMINATION
US7728589B2 (en) 2002-05-20 2010-06-01 Massachusetts Institute Of Technology Method for sequence determination using NMR
US7737692B2 (en) 2002-05-20 2010-06-15 Massachusetts Institute Of Technology Method for sequence determination using NMR
US8018231B2 (en) 2002-05-20 2011-09-13 Massachussetts Institute Of Technology Method for sequence determination using NMR
EP1590648A2 (en) * 2002-05-20 2005-11-02 Massachusetts Institute Of Technology Novel method for sequence determination using nmr
US7592152B2 (en) 2004-03-10 2009-09-22 Massachusetts Institute Of Technology Chondroitinase ABC I and methods of analyzing therewith
US7662604B2 (en) 2004-03-10 2010-02-16 Massachusetts Institute Of Technology Chondroitinase ABC I and methods of production
US7553950B2 (en) 2004-03-10 2009-06-30 Massachusetts Institute Of Technology Chondroitinase ABC I polynucleotides
US7507570B2 (en) 2004-03-10 2009-03-24 Massachusetts Institute Of Technology Recombinant chondroitinase ABC I and uses thereof
US8338119B2 (en) 2004-03-10 2012-12-25 Massachusetts Institute Of Technology Chondroitinase ABC I and methods of degrading therewith
US8209132B2 (en) 2004-04-15 2012-06-26 Momenta Pharmaceuticals, Inc. Methods and products related to the improved analysis of carbohydrates
US8000904B2 (en) 2004-04-15 2011-08-16 Momenta Pharmaceuticals, Inc. Methods and products related to the improved analysis of carbohydrates
US8529889B2 (en) 2004-06-29 2013-09-10 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
EP2450441A2 (en) 2005-11-03 2012-05-09 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
EP2441830A2 (en) 2005-11-03 2012-04-18 Momenta Pharmaceuticals, Inc. Heparan sulfate glycosaminoglycan lyase and uses thereof
US7842492B2 (en) 2007-01-05 2010-11-30 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
US8846363B2 (en) 2007-01-05 2014-09-30 James R. Myette Compositions of and methods of using sulfatases from Flavobacterium heparinum
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
WO2008153504A1 (en) * 2007-06-15 2008-12-18 Agency For Science, Technology And Research System and method for representing n-linked glycan structures
US8435795B2 (en) 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US9068957B2 (en) 2011-02-21 2015-06-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations

Also Published As

Publication number Publication date
JP4824170B2 (ja) 2011-11-30
US7139666B2 (en) 2006-11-21
CA2370539A1 (en) 2000-11-02
US20040204869A1 (en) 2004-10-14
US20090119027A1 (en) 2009-05-07
US20030191587A1 (en) 2003-10-09
EP1190364A2 (en) 2002-03-27
CA2643162C (en) 2018-01-02
US7412332B1 (en) 2008-08-12
CA2643162A1 (en) 2000-11-02
US7110889B2 (en) 2006-09-19
WO2000065521A3 (en) 2001-10-25
US20080301178A1 (en) 2008-12-04
US20070066769A1 (en) 2007-03-22
US20040197933A1 (en) 2004-10-07
CA2370539C (en) 2009-01-06
US6597996B1 (en) 2003-07-22
US7117100B2 (en) 2006-10-03
JP2002543222A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
CA2370539C (en) System and method for notating polymers
US8018231B2 (en) Method for sequence determination using NMR
Lawrence et al. Evolutionary differences in glycosaminoglycan fine structure detected by quantitative glycan reductive isotope labeling
Tang et al. Automated interpretation of MS/MS spectra of oligosaccharides
Pepi et al. Developments in mass spectrometry for glycosaminoglycan analysis: a review
Huang et al. LC-MS n analysis of isomeric chondroitin sulfate oligosaccharides using a chemical derivatization strategy
US20110159476A1 (en) Methods and apparatus for characterizing polymeric mixtures
Zamfir et al. Structural characterization of chondroitin/dermatan sulfate oligosaccharides from bovine aorta by capillary electrophoresis and electrospray ionization quadrupole time‐of‐flight tandem mass spectrometry
Sugahara et al. Structural Studies on the Hexasaccharide Alditols Isolated from the Carbohydrate-Protein Linkage Region of Dermatan Sulfate Proteoglycans of Bovine Aorta: DEMONSTRATION OF IDURONIC ACID-CONTAINING COMPONENTS (∗)
Wang et al. Recent advances in mass spectrometry analysis of low molecular weight heparins
Tissot et al. Software tool for the structural determination of glycosaminoglycans by mass spectrometry
WO2002044714A2 (en) System and method for integrated analysis of data for characterizing carbohydrate polymers
Hounsell et al. Computer-assisted interpretation of1H-nmr spectra in the analysis of the structure of oligosaccharides
Capila et al. Methods for structural analysis of heparin and heparan sulfate
Hogan Methods in automated glycosaminoglycan tandem mass spectra analysis
Roberts et al. tal Health, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.* To whom correspondence should be addressed. E-mail: ramnat@ mit. edu
Mischnick Polysaccharide Sequencing
Raman et al. Informatics Concepts to Decode Structure-Function Relationships of Glycosaminoglycans
von der Lieth Experimental Methods for the Analysis of Glycans and Their Bioinformatics Requirements

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2370539

Country of ref document: CA

Ref country code: CA

Ref document number: 2370539

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 614193

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 2000923599

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000923599

Country of ref document: EP